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ABSTRACT 
 
 
Biomarker detection represents an important task for many scientific fields such as 
disease diagnosis, biodefense, environmental monitoring and biological research. In this 
research, micro resistive pulse immunoaggregation sensors were studied to quantitatively 
detect macromolecular and cellular biomarker concentrations. First, to prove the concept 
of the immunoaggregation assay and resistive pulse sensing, goat anti-rabbit IgG, used as 
a model biomarker, was detected by the micro resistive pulse immunoaggregation sensor. 
A detection range from 16.0 to 160 ng/mL was achieved. The human ferritin in 10% fetal 
bovine serum was then detected to prove the device’s performance in a complex media. A 
detection range from 0.104 to 208 ng/mL was achieved. In addition, the studies showed 
that the detection range can be shifted to lower and higher concentrations by decreasing 
and increasing MP concentrations, respectively. 
Second, the multiplexed immunoaggregation assay was also studied in this research 
to achieve multiple biomarker detection in a single test. A mixture consisting of multiple 
types of MPs functionalized by different antibody with different sizes and magnetic 
properties was used for testing the multiplexed assay. 2.00 µm non-magnetic MPs coated 
with rabbit anti-mouse IgG antibody and 2.80 µm magnetic MPs coated with goat anti-
human ferritin antibody were used to detect the concentration of mouse anti-rabbit IgG and  
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human ferritin, respectively. Detection ranges from 5.20 to 208 ng/mL and 3.10 to 51.2 × 
103 ng/mL were achieved for human ferritin and mouse anti-rabbit IgG detection. 
Next, a two-stage resistive pulse sensor was invented to detect target cells in a 
mixed cell population. S. cerevisiae and Chlorella were used as target cells and control 
cells, respectively. The specific capture efficiency of S. cerevisiae was greater than 94.8%, 
while the nonspecific capture efficiency was less than 3.4%. S. cerevisiae ratio 
measurements in a mixture with Chlorella showed that for S. cerevisiae to Chlorella ratios 
ranging from 1.0 to 2.0, the measurement errors were less than 7%, while the errors were 
20% to 32% for lower ratios, ranging from 0.1 to 0.5, caused by nonspecific attachment. 
The testing results demonstrated that the immunoaggregation biomarker sensor and 
MP cellular sensor enable reliable detection of target macromolecular and cellular 
biomarkers in samples at very low concentrations, without the fluorescence and enzyme 
labeling of biomarker. These innovative biosensors will lead to a fast and cost-effective 
bioassay instrument for disease diagnosis, environmental monitoring and homeland 
security. 
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CHAPTER I 
INTRODUCTION 
 
 
 
1.1 Introduction 
 
Quantitative detection of biomarkers, as indicators of biological states, is an 
important task in disease diagnosis [2] [3], biodefense [4], environmental monitoring [5] 
and biological research [6] [7] [8] [9]. In medicine, macromolecular and cellular 
biomarkers are often isolated from serum, urine or other fluids [10] [11] [12]. Quantitative 
detection of these biomarkers is a powerful tool in the early detection/diagnosis stages of 
disease, in the monitoring of the effectiveness of treatment and the discovery of new drugs, 
etc. [13]. On the other hand, due to the complexity of human biology and the heterogeneity 
of diseases, a single biomarker is insufficient to provide enough information for disease 
diagnosis [14] [15] [16]. Thus, a device for disease related biomarker detection should meet 
two basic requirements: quantitative detection with high sensitivity and multiplex 
capability. A rapid and portable detection with minimum steps is also essential for on-site 
disease diagnosis. 
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1.2 Motivation 
 
An immunoassay is the most commonly used technology that enables highly 
sensitive detection of macromolecular and cellular biomarkers [17] [18]. Compared with 
conventional immunoassay, recent studies show that immunosensor chips are promising 
platforms for immunoassays with many advantages including low sample consumption, 
high sensitivity, rapid, automatic and capable of multiplexed detection [19] [20] [21] [22]. 
The recent development in label-free and fully integrated immunosensor chips 
further improves their performance and extends their application to on-site disease 
diagnosis [23] [24]. A label-free immunosensor chip avoids labeling of detection antibody, 
which not only reduces the assay steps, but also eliminates the loss of binding affinity due 
to the labeling process [25] [26]. Microparticles, as micro carriers, are a promising platform 
for immunoassays due to their large surface to volume ratio, which increases the interaction 
between the target molecule and capture antibody. Recently, several approaches to label-
free immunoassays based on the immunoaggregation of MPs have been developed to 
quantitatively detect macromolecule concentrations. However, these methods rely on 
bulky and expensive off-chip instruments including light/fluorescence microscopy, flow 
cytometry and light scattering [27] [28][29][95], making them impractical for on-site 
diagnosis. Thus, the first objective of this project is to develop a label-free, compact, low 
cost immunoaggregation assay based on a micro resistive pulse sensor for quantitative 
biomarker detection. 
Due to the complexity of human biology and the heterogeneity of diseases, single 
biomarker detection is insufficient to provide enough information for disease diagnosis [14] 
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[15] [16]. Based on the solid support for capture antibody immobilization, two strategies 
for multiplexed detection are planer arrays and suspension arrays (immunoassays based on 
MPs) [30]. The recovery of the antibody activities in a planer array for reuse is difficult 
[31]. The MP encoding methods can be further categorized into spectrometric, electronic, 
graphical or physical methods [30]. However, most of these encoding methods are 
dependent on optical detection [32] [33] [30] [34] [35]. Although electric encoding, such 
as radio frequency (RF) encoding, only requires an electronic reader [36], the large size of 
RF chips (~8 mm × 1 mm × 1 mm) limits their application in immunosensor chips. Thus, 
the second objective of this project is to study the multiplexed methods for micro resistive 
pulse immunoaggregation sensors based on the physical encoding approach, such as the 
size and magnetic properties of the MPs. 
Cellular biomarkers, such as pathogen cells and cancer cells, represent another 
important class of biomarkers for many applications such as disease diagnosis, food 
industry, environmental monitoring, biodefense and biological research. Two major 
strategies for cellular biomarker detection are polymerase chain reaction (PCR) and 
immunoassay [37]. Although a PCR-based sensor chip has a high sensitivity, the PCR-
based biosensor chip is complicated because of the need for temperature control for 
thermocycling and on-chip cell lysis [38] [39]. For an immunosensor chip, cellular 
biomarker detection is based on the specific binding between receptors on the cell surface 
and antibody immobilized on a solid surface [38] [9]. Thus the surface immobilization of 
antibody is crucial for the sensitivity of an immunosensor [9]. However maintaining the 
function of surface immobilization is difficult due to the limited lifetime of the antibody, 
and it is also a challenge to reproduce the surface antibody coverage for reuse of the sensing 
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surface [37]. Microparticles are an emerging technique for surface modification of 
immunosensor chips [31]. The use of functionalized MPs can significantly reduce the 
difficultly in the surface modification of immunosensor chips. Thus, the third objective of 
this project is to develop a new two-stage micro resistive pulse sensor with a surface 
coating of antibody functionalized MPs for pathogen cell detection. A detailed review of 
immunosensor chips is presented in Chapter II. 
 
1.3 Research objectives 
 
The main research objective of this project is to develop label-free, rapid, portable 
and multiplexed micro resistive pulse sensors (RPSs) to quantitatively detect 
macromolecule and cellular biomarkers. Specific objectives are described in detail in the 
following sections. 
 
Part I Study of the micro resistive pulse sensor (RPS) chip and quantitative 
immunoaggregation assay 
 Design and fabricate the RPS chip using soft lithography micromachining. 
 Calibrate the RPS chip to ensure its sizing and counting performance.  
 Study the performances of the RPS chip and the immunoaggregation assay using 
goat anti-rabbit IgG as a model biomarker. 
 Study the performances of the RPS chip and the immunoaggregation assay for 
human ferritin detection in a complex media.  
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 Demonstrate the tunable detection range of the RPS chip using various MP 
concentrations. 
 
Part II Study of the multiplexed RPS immunoaggregation chips  
 Study the performance of the immunoaggregation assay using 2.00 µm antibody 
functionalized MPs. 
 Design and fabricate the two-stage RPS chips. 
 Demonstrate the feasibility of the multiplexed immunoaggregation assay for human 
ferritin and mouse anti-rabbit IgG measurement. 
 
Part III Study of the two-stage RPS chips for pathogen cell detection 
 Design and fabricate the two-stage RPS chips. 
 Study the performance of the two-stage RPS in terms of specific capture efficiency 
and nonspecific capture efficiency. 
 Demonstrate the feasibility of pathogen cell detection in a mixed population with 
control cells. 
 
1.4 Summary 
 
The rest of this dissertation is arranged as follows: in Chapter II, the background 
and a literature review on recent developments in immunosensor chips are presented. Next, 
in Chapter III, to prove the concept of the immunoaggregation assay in a micro resistive 
pulse sensor, a model biomarker detection is studied. In Chapter IV, the micro resistive 
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pulse sensor and immunoaggregation assay are applied to human ferritin detection in a 
complex media. Various MP concentrations are also applied to human ferritin detection to 
achieve a tunable detection range. In Chapter V, a two-stage RPS and immunoaggregation 
assay using a mixture of MPs for multiplexed detection is presented. In Chapter VI, a two-
stage RPS coated with antibody functionalized MPs for cellular biomarker (pathogen cell) 
detection are presented. Finally, the conclusions and future thoughts are presented in 
Chapter VII. 
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CHAPTER II 
BACKGROUND AND LITERATURE REVIEW 
 
 
 
2.1 Immunosensors for macromolecule detection 
 
Immunoassays are the most widely used tools for macromolecule detection, based 
on the recognition of specific binding between target molecule and capture antibody [23]. 
Recent studies on immunosensor chips as promising platforms for immunoassays show 
that immunosensor chips have many advantages compared with the conventional Enzyme-
Linked Immunosorbent Assay (ELISA) including low sample consumption, high 
sensitivity, fast, automatic and capable of multiplexed detection [40] [22]. On-site 
diagnostic applications also require the development of label-free, fully integrated, low-
cost and multiplexed immunosensors with minimum assay steps [23] [24]. In this chapter, 
immunosensors for macromolecule detection are reviewed in respect of the following 
aspects: immunosensor chips for macromolecule detection, multiplexed immunosensor 
chips and immunosensor chips for cellular biomarker detection. 
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2.1.1 Enzyme immunoassay/Enzyme-linked immunosorbent assay 
 
 
Figure 2.1 A sandwich ELISA typically requires six steps and runs on a microtiter plate 
 
The most commonly used technique to detect macromolecule at present is the 
Enzyme immunoassay/Enzyme-linked immunosorbent assay (EIA/ELISA) [17] [18]. 
Performing an ELISA involves labeling the enzyme on target macromolecule and 
determining the macromolecule concentration by monitoring the generation of colored 
enzymatic products. Before the invention of ELISA, the immunoassay was conducted 
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using radioimmunoassay (RIA) [41] [42] [43], which not only introduced safety concerns 
regarding the use of radioactive labels [44], but also suffered from a poor reproducibility 
[45]. In ELISA, the enzyme labeled on the target biomolecule is stable and only introduces 
color change without any health hazard problems [46] [47] and the sensitivity of ELISA is 
comparable with the RIA [48]. As a nonradioactive immunoassay, ELISA has been wildly 
used in medicine, various industries and biomedical research [44], and has proven to be 
both robust and reliable [21]. Currently, there are four types of ELISA: direct ELISA, 
indirect ELISA, sandwich ELISA and competitive ELISA [23]. Using a sandwich ELISA 
as an example, the general testing procedures are shown in Figure 2.1.  
A conventional ELISA is usually conducted in the microtiter plate, as shown in 
Figure 2.1. . A sandwich ELISA requires the following steps, 1) coating the capture 
antibody on the well, 2) blocking remaining binding cites to avoid nonspecific binding, 3) 
capturing of the target molecule, 4) washing free target molecule, 5) binding the detection 
antibody with enzyme labels and 6) generation of colored products. At least 100 µL sample 
is delivered into each micro well [35]. Using a larger volume of micro well has two 
drawbacks: 1) large consumption of expensive sample, and 2) long diffusion time of 
regents [49]. In each step, the incubation may take from several hours to one day to 
complete. Thus, a conventional ELISA is a time-consuming and labor-intensive process, 
which limits its clinical application [50] [51]. A microtiter plate reader is bulky, expensive 
and requires skilled personal, which is another drawback of a conventional ELISA [44] 
[51]. 
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2.1.2 Recent development in immunosensor techniques 
 
Benefiting from a large surface area to volume ratio and miniaturized structure, 
microfluidics immunosensors have many advantages compared with a conventional 
ELISA, including low sample consumption, rapid detection, high sensitivity and portable, 
capabilities for multiplexed and automatic detection [19] [20] [21] [22]. In an 
immunosensor, target molecule recognition is also achieved through specific binding 
between target molecule and capture antibody as in the conventional ELISA shown in 
Figure 2.1. In order to report this binding event, a label-based immunosensor uses 
fluorescent, luminescent or electrochemical labels to generate a detectable signal. In 
comparison, a label-free method measures the change of mass, electrical or other properties 
caused by the presence of target molecule without any labeling process [52]. Thus, 
immunosensors can be categorized into label-based or label-free methods [53].  
Based on the types of detection signal, the label-based immunosensor chips can be 
further divided into two groups, optical immunosensors and electrochemical 
immunosensors. Types of optical labels include fluorescence [54][55], luminescence [56], 
colorimetric [57] [58] and micro/nano particle labels [59] [60]. Fluorescence is the most 
commonly used label because of its many advantages including high sensitivity and ease 
of detection [35] [61]. Laser diodes are commonly used as a light source for fluorescence 
excitation [62] [63]. An alternative for laser diodes are LEDs [64] [65], which are lower in 
cost but have more divergence. Compared with fluorescent labels, the use of luminescent 
labels offers a simpler optics setup because luminescent emission is generated through a 
photochemical reaction and a light source is not required. The use of a luminescent label 
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also increases the signal to noise ratio (SNR) by the reduction of background interference 
caused by excitation light. The colorimetric labeling method is easy to use and cost 
effective, and is well-established in conventional ELISA. However, it also suffers from 
poor sensitivity compared with other labeling methods. Quantum dots are also used as 
labels in immunosensor chips to address the problems of fluorescent labels including photo 
bleaching, broad emission spectrum and limited in color options [66] [67]. However, 
quantum dots are difficult to synthesize, to functionalize, have limited shelf life and are 
more expensive than fluorophores [68]. Two major concerns with these optical labeling 
methods are: 1) difficult to fabricate the on-chip optics including lens [65], filter [69], 
waveguide [63] [64], light source [27] [70] and detector [71]; and 2) limited in multiplexed 
assay because fluorescence has a broad emission spectrum and less color options [61].  
Another type of label-based immunosensor is the electrochemical immunosensor. 
Usually, an electrochemical immunosensor has three electrodes which are the working 
electrode, counter electrode and reference electrode. The working electrode is coated with 
capture antibody. The use of label-based electrochemical immunosensors involves: 1) 
labeling with enzyme, or other electroactive molecules or nanoparticles; and 2) measuring 
the current as a function of applied voltage between the working and reference electrodes 
[52]. The measured current is proportional to the enzyme activity and represents the target 
molecule concentration. Besides enzyme labels, nanoparticle labels are also used in 
electrochemical immunosensors. Nanoparticles have a large surface to volume ratio and 
high binding efficiency which leads to a high sensitivity in macromolecule detection [72]. 
The nanoparticle labels used in electrochemical immunosensor chips include metal 
particles [73] [74], carbon nano tubes [75] [76] and quantum dots [77] [78]. Because the 
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electrochemical immunosensors only have electronic components they are cost effective 
and easy to integrate on a sensor chip. However, the disadvantages of electrochemical 
immunosensors include: 1) difficulties in maintaining the functionality of the surface 
modification for a long time due to the instability of antibody [79]; 2) a large applied 
voltage may damage the modification of capture antibody on the electrodes [52]; and 3) 
the performance of electrochemical immunosensors is affected by nonspecific absorption, 
pH and ionic concentration [68] [52]. 
 
 
Figure 2.2 Sensing principle of surface plasmon resonance (SPR) 
 
A label-free immunosensor is preferred for macromolecule detection for two major 
reasons. Firstly, the surface functionalization of a label-free immunosensor is simple and 
only requires immobilization of capture antibody on the sensor chip surface, compared 
with a label-based immunosensor chip which has a “capture antibody – target 
macromolecule – detection antibody” sandwich structure; secondly, labeling of detection 
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antibody may reduce the binding affinity of the capture antibody [25] [26]. The label-free 
immunosensors can also be categorized into optical immunosensors, electrochemical 
immunosensors and mechanical immunosensors [61]. The label-free optical 
immunosensors include surface plasmon resonance (SPR) spectroscopy [80], surface-
enhanced Raman spectroscopy (SERS) [81], capillary electrophoretic immunoassays 
(CEIA) [82] [83], photonic crystals sensors [84], optical microcavity resonators [85], 
reflective interferometry [86] and imaging ellipsometry [87]. The sensing principle of an 
SPR is shown in Figure 2.2. Antibody is immobilized on a metal film. An incident light 
containing multiple incident angles is reflected on the metal film. Free electrons at the 
metal surface absorb the incident light at a certain incident angle (SPR angle) and transfer 
it to a surface plasmon wave. The absorbed light can be observed by a detector. The SPR 
angle is very sensitive to the surface refractive index. The binding of capture antibody and 
target molecule causes a change of refractive index of the metal film, which leads to a shift 
of SPR angle, as shown in Figure 2.2. Thus the target molecule concertation can be detected 
through the measurements of the SPR angle. Due to the complicated optics setup, the 
optical detection instruments are very expensive. For example, SPR is a well-established 
and commercially available instrument. A commercially available SPR instrument (for 
example, Biacore SPR Systems, GE) costs $120,000–$250,000, and each test may 
consume one electrode chip, which costs $60-$120 [88]. As discussed above, another 
common problem shared by all optical sensor chips is the fabrication of on-chip optics and 
detectors. The details of label-free optical immunosensor chips are reviewed in [40] [61] 
[68]. 
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Figure 2.3 Sensing principle of nanowire-based FET immunosensor 
 
In the category of label-free immunosensors, electrochemical and mechanical 
immunosensors are preferred because most of them only require electrical components, 
which are easy to integrate on sensor chips. Label-free electrochemical sensors are based 
on a change in electrical properties (dielectric constant, charge state [52]) caused by the 
binding between antigen and antibody. For electrochemical impedance spectroscopy (EIS) 
based sensors, the antibody coated on the working electrode is used to bind the target 
macromolecule. This binding event will trigger the impedance change and is observed 
through the EIS [89]. Both multi frequency and signal frequency excitation are applied to 
EIS to detect the impedance changes [72]. The use of signal frequency measurement 
reduces the testing time and enables a real-time detection. Another label-free approach is 
the field effect transistor (FET) sensor, as shown in Figure 2.3. For a nano wire FET, the 
conductance between source and drain is controlled by the voltage applied at the gate 
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electrode. The nano wire coated with capture antibody acts as the gate electrode. The target 
molecule has a net negative or positive charge in aqueous solution. Thus, the binding 
between target molecule and capture antibody will increase or decrease the surface charge 
of the nano wire (gate electrode) and change the conductance between the drain and source 
electrodes. Thus, the binding event and the concentration of target molecule can be 
monitored by measuring the conductance change. Nano wire FET has an ultrahigh 
sensitivity which may enable single molecule detection [90]. However, fabrication of nano 
wire FET and maintaining the activity of capture antibody are difficult.  
 
 
Figure 2.4 Sensing principle of cantilever immunosensor 
 
Mechanical label-free methods are based on the mass change caused by target 
macromolecule binding. For example with a micro cantilever sensor, as shown in Figure 
2.4, the cantilever surface is immobilized with capture antibody and is able to capture the 
target macromolecule. This binding event leads to an increase of mass of the cantilever 
beam, and further causes the deformation of the micro cantilever. This deformation can be 
detected through optical detection [91] or electrical detection [92]. However, the micro 
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cantilever beam sensor is easily affected by the environment. For example, a small 
temperature change during a measurement will also cause a deflection of the micro 
cantilever, causing false positives. A quartz crystal microbalance (QCM) is another well-
established immunosensor based on mass change. The binding of target molecule increases 
the mass on the QCM surface and causes displacement of the crystal oscillation, which 
leads to a resonant frequency shift. Thus, the measured resonant frequency represents the 
binding event and target macromolecule concentration. However, QCM is very sensitive 
to temperature variations, electronic noise and mechanical drift [93]. 
The above mentioned immunosensor chips are based on immobilization of capture 
antibody on a planner surface, which is a tedious process and requires skilled personnel. 
More importantly, the immobilized capture antibody has a short life cycle. Microparticles, 
as micro carriers, are another option as solid support for antibody immobilization. 
 
2.1.3 Immunosensor based on microparticles 
 
As discussed above, most immunosensor chips use planner surfaces in the 
microchannel as solid supports for capture antibody. The surface of the MPs is another 
option as a solid support with many advantages. Firstly, MPs have an extremely large 
surface to volume ratio, which enables high efficiency interactions between target 
macromolecule and capture antibody coated on the MPs. Secondly, MPs are easy to 
manipulate. The use of MPs not only simplifies the process of immobilization of the 
capture antibody, but also eliminates the difficulties in recovery of biological activity of 
the capture antibody for reuse of the immunosensors. Thirdly, compared with spatially 
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dividing a plane surface and coating each sub-plane with different antibody for 
multiplexing, it is much more convenient to coat MPs with various capture antibody for a 
multiplexed immunoassay [35]. Microparticle based immunoassays are well developed and 
commercially available, for example with the xMAP technology. An immunoassay based 
on MPs with detection by fluorescent flow cytometry is shown in Figure 2.5. 
 
   
Figure 2.5 Working mechanism of immunoassay based on microparticles and flow 
cytometry for multiple molecule detection 
 
As shown in Figure 2.5, the capture antibody coated on the MPs target the 
macromolecule and detection antibody tagged with different color fluorescent dyes are 
formed in the sandwich ELISA structure. To achieve a multiplexed detection, MPs encoded 
with different florescent colors flow through the sensing area of a flow cytometry. A laser 
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beam provides the florescent excitation. The passage of a particle causes forward scatter 
and side scatter of the laser beam. Beam splitters and filters are used to decode the 
florescent color and determine the target macromolecule concentration. Although MP 
based immunosensors have many advantages, most of these chips rely on optical detection 
[35]. Recent studies show that the immunoaggregation assay is an emerging technique for 
quantitative biomarker detection [94] [95] [28] . Currently, most immunoaggregation 
assays rely on optical detection [29] [96] [27]. Because the immunoaggregation assay is 
based on MP aggregation triggered by target molecule, a resistive pulse sensor, which is 
highly sensitive to the size change of MPs, is an ideal detector for the immunoaggregation 
assay. 
 
2.1.4 Immunoaggregation assay 
 
Comparing with ELISA, an immunoaggregation assay has many advantages. 
Firstly, an immunoaggregation assay does not require labeling steps. Normally, an 
immunoaggregation assay only has one step, which significantly reduces the assay time 
and labor intensity. Secondly, microparticles have large binding surface to volume ratio 
and fast diffusion rate, which promote the reaction between analyte and capture antibody. 
Thirdly, the surface modification of microparticles is simple. It is also convenient to 
conduct a multiplexed assay using microparticles coated with various capture antibodies. 
Fourth, microparticles are easy to manipulate in a microfluidic device. Thus, 
immunoaggregation assays are suitable for the use in miniaturized systems [95]. 
Conventional immunoaggregation assays were introduced by Singer and Plotz [97]. 
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Commercially available immunoaggregation assay kits based on conventional 
immunoaggregation assays are capable of identifying bacterial, fungal and viral diseases 
and macromolecule including hormones and proteins [94]. There kits are inexpensive, 
portable and able to make detection of biomarkers by the naked eye. In order to conduct a 
conventional immunoaggregation assay, unknown sample, negative control (without 
biomarker) and positive control (with biomarker) are mixed with antibody functionalized 
microparticles. The presence of target biomarkers causes aggregation of the antibody 
functionalized microparticles. If the unknown sample contains target biomarkers, the 
presence of target biomarkers can be identified by comparing test results between the 
unknown sample and positive control (visible aggregation cluster are formed in both of 
them). However, conventional immunoaggregation kits are unable to quantitatively 
measure the biomarker concentration and only able to detect the presence of biomarkers. 
Recent studies proved that the immunoaggregation assay is also able to quantitative 
analysis of macromolecule concentration. Depending on the state of the aggregates [95], 
the on-chip immunoassays were performed as a doublet assay [29] [96] [27] and a cluster 
assay [94] [95] [28]. The detection methods for immunoaggregation assays include optical 
detection (turbidimetry [98], light microscopy [27] [28], fluorescent microscopy [29] and 
light scattering [29]), magnetophoresis [96], and resistive pulse sensing [1] [99]. High 
sensitive immunoaggregation assays were also achieved through the alignment of 
aggregates in sensing channels using hydrodynamic [100], magnetic [27] or ultrasonic [95] 
focusing. Among these detection methods, the turbidimetry is based on bulk detection 
which measures the loss of intensity of transmitted light caused by scattering of the 
aggregates suspension. The turbidimetry is unable to detect individual aggregate, thus it 
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has a poor detection limit [28]. Light scattering is another optical detection method. Pamme 
et al reported a microfluidic device for counting and sizing immunoaggregates using laser 
light scattering [101]. The scattering density is proportional to the volume of aggregates. 
A commercial immunoaggregation assay kit for C-Reactive protein (CRP) detection was 
tested in their studies. A detection limit of 100 ng/mL was achieved. However, from their 
measurement results, light scattering was also unable to differentiate microparticle 
doublets. Although distinguishing microparticle doublets is extremely difficult, 
quantitative detection of microparticle doublet is able to increase the detection sensitivity 
[29] [102]. Light microscopy is simple and easy to obtain, which is suitable for resource-
limited area. Recently, Wu et al demonstrated that an immunoaggregation assay based on 
light microcopy is able to detect human ferritin concentrations as low as 0.1 ng/mL, which 
is lower than the detection limit of most commercial ELISA kits [103]. This high sensitive 
detection was achieved through doublet assay. However light microscopy has a manual 
readout which means it is labor intensive and only has a low throughput. Wiklund et al 
reported a fluorescence microscopy based image analysis method for classification of 
singlets and doublets of microparticles [102]. By using this method, microparticle singlets, 
doublets and triplets can be differentiated in the measurement results. Using fluorescent 
microscopy to differentiate aggregate doublets not only requires a long assay time due to 
the use of an image recognition algorithm, but also requires large data storage which make 
it impractical for real-time detection. Kim et al also demonstrated an immunoaggregation 
assay based on magnetophoresis [96]. In their study, the presence of mouse IgG caused the 
aggregation of 1 µm polystyrene microparticles and 50 nm magnetic particles. Both of 
polystyrene microparticles and magnetic particles were coated with goat anti-mouse IgG. 
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The aggregates’ velocity introduced by the magnetic field was used as an indicator of 
mouse IgG concentration. The detection limit of 15.6 ng/mL was achieved. They also used 
fluorescent encoded microparticles to prove this method can be applied to a multiplexed 
detection. However, image analysis is required to track the movement of aggregates, which 
increases the assay time and reduces the throughput of this device. The aforementioned 
methods are all based on optical detection. Recent studies also utilized resistive pulse 
sensors for immunoaggregation assay. A resistive pulse sensor only involves electrical 
detection and has a high accuracy in particle sizing, which makes it an ideal detector for 
immunoaggregation sensing. The use of resistive pulse sensors for immunoassays is 
reviewed in next section 2.1.5. 
As mentioned before, in order to achieve a highly sensitive detection, particle 
forcing techniques were applied to the immunoaggregation assay including hydrodynamic 
[100], ultrasonic [95] [104], capillary electrophoresis (CE) [105], and magnetic [27] 
focusing techniques. Nilsson et al proved that the capillary electrophoresis is able to 
separate microparticles from their aggregates based on their electrophoretic mobility [105]. 
The electrophoretic mobility is determined by the electric charge of antibody coated on 
microparticles. In order to detect the presence of human chorionic gonadotropin (hCG), 
two kinds of antibody were used in their experiments (antibody B is directed against the α-
subunit of hCG and antibody A is directed against the β-subunit of hCG). Only one type of 
antibody was coated on the each microparticle. The mobility of antibody B coated 
microparticles is higher than the mobility of antibody A coated microparticles. Thus, the 
aggregates formed by these two types of microparticles has an intermediate mobility 
between these two types of single microparticles. CE was then used to separate two types 
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of single microparticles and their aggregates. However, CE detection only has a low 
throughput and low sensitivity.  
Under an ultrasonic standing ware (USW) field, microparticles are driven to the 
pressure node of the standing wave. Instead of relying on Brownian motion, the use of 
USW force increases the probability of microparticle collisions and further enhances the 
sensitivity of immunoaggregation assay [106]. Thomas et al demonstrated that the use of 
USW focusing significantly reduces the lower detection limit from 300 ng/mL to 230 
pg/mL comparing with a conventional test-card procedure [107]. However, USW relies on 
radio frequency exaction, which not only requires a complicate setup, but also introduces 
bubbles into the microfluidics system which will cause a false detection of aggregates. 
Afshar et al demonstrated a 3D magnetic focusing method to align particles in the 
microchannel in order to aid the microparticle doublet recognition. The microparticle 
doublet was detected under a light microscope. This method was used for the detection of 
the bBSA concentrations in a model immunoaggregation system. A detection limit of 
approximately 400 pg/mL was achieved. One problem for magnetic focusing is that 
magnetized microparticles tend to form nonspecific aggregates, which will be counted as 
immunoaggregates and lead to errors in biomarker concentration measurement. 
Although focusing of aggregates is able to aid in the optical detection of aggregate 
doublets, quantitative detection of microparticle doublets is still a problem in 
immunoaggregation assays. It is worth mentioning here focusing methods are not limited 
to these four methods. A detailed review of particle focusing methods for microfluidic 
devices can be found in [108]. 
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2.1.5 Micro resistive pulse immunosensors 
 
Resistive pulse sensing/Coulter counter principle has been applied in particle sizing 
and counting since the 1940s [109]. A resistive pulse sensor consists of three components 
including a sensing channel, a pair of inlet/outlet reservoirs and a pair of electrodes. The 
transit of a particle through the sensing channel causes a resistive pulse between the 
electrodes. The amplitude of the resistive pulse represents the size of the particle, and the 
counts of resistive pulses is used to calculate the particle concentration. The conventional 
resistive pulse sensor is well-established instrument and commercial available. The 
detection range of a commercial device is from 0.4 to 1600 µm in diameter (e.g. Multisizer 
4 COULTER COUNTER, Beckman Coulter). 
Recent studies show that micro resistive pulse sensors are promising tools for 
macromolecule detection. There are two major resistive pulse sensing strategies for 
macromolecule detection: 1) direct detection using nanopores, and 2) using microparticles 
as biomarker carriers to amplify the resistive pulse signal. Because the sensitivity of a 
resistive pulse sensor is inversely proportional to the volume of the sensing channel [109], 
a resistive pulse sensor with a nano scale sensing channel (10 to 100 nm [47]–[55]) has an 
extremely high sensitivity but a low limit of detection, which is able to directly detect nano 
bio-objects, such as DNA [110], [111], RNA [112], virus [113], [114] and protein [115]–
[117]. Three types of nanopores for macromolecule detection have been utilized: biological 
pores [118], artificial pores [119] [120] and hybrid nanopores [121]. Comparing with 
biological pores, such as α-hemolysin pores, artificial pores have many advantages 
including tunable pore size, stability over a wide range of voltages, temperatures, and pH 
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[119]. In addition, three parameters of the resistive pulses can be used for macromolecule 
characterization: amplitude of the pulse (indicative of object size), pulse width (indicative 
of object mobility) and blockage (indicative of specific binding) [121]. 
Another strategy for macromolecule detection is to use microparticles to amplify 
the resistive pulse signal. Carbonaro et al reported an immunoassay based on resistive pulse 
sensing and antibody functionalized microparticles to detect the presence of biomarkers 
[115]. In this methods, 470 nm microparticles were coated with capture antibody, after 
antigen and detection antibody were captured on the microparticles, the microparticles’ 
diameter increased from 470 nm to 490 nm. This diameter change was detected by the RPS 
as an indicator of the presence of target biomarkers. They also demonstrated that the use 
of various antibody functionalized microparticles is able to achieve a multiplexed detection. 
However, there are two limitations of this device: 1) the resistive pulse change due to the 
small change of diameter (because of the nano size of the biomarkers) is difficult to 
measure, and 2) this method is unable to evaluate the concentration of target biomarkers. 
 
2.2 Multiplexed immunosensors 
 
The multiplexed detection of disease related biomarkers is important for two major 
reasons: firstly, due to the complexity of human biology and the heterogeneity of diseases, 
single biomarker detection is insufficient to provide enough information for disease 
diagnosis [14] [15] [16]. Secondly, the multiplexed detection of biomarkers associated with 
different stages or classification of diseases is able to increase the accuracy in disease 
diagnosis [122] [123] [124] [125]. Based on the solid support for capture antibody 
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immobilization, the multiplexed approaches are divided into two categories [30] [126]: 
planar arrays and suspension arrays (immunoassays based on micro particles). In term of 
planar arrays, the surface encoding method involves spatially coating support surface in an 
array with multiple types of capture antibody [127]; while the suspension arrays use 
microparticles as capture antibody carriers. 
 
2.2.1 Planar arrays 
 
Label-based multiplexed immunosensors. A planar array immunosensor is well- 
established as high-throughput devices with high sensitivity less sample consumption [128]. 
Base on the labeling method, planar arrays immunosensors can be categorized as optical 
immunosensors (fluorescence [15] [129], luminescence [130], [131], [132], colorimetric 
[133], [134]) and electrochemical immunosensors [135]. The solid support for a planar 
array includes glass slide, nitrocellulose membranes, microparticles, or microtiter plates. 
However, the most challenge for a planar array is the surface modification of a planar array. 
Currently, the fabrication methods of a planar array include contact printing, non-contact 
printing, microfluidics-based printing, microstamping, lithography, cell-free protein 
expression microarray [136]. The drawback for these methods includes antibody 
compatiabltity, low signal to noise ratio [128]. The lack of specific capture molecule is 
another problem that limits the broader use of planar microarray technology[128]. 
Label-free multiplexed immunosensors. Label-free multiplexed immunosensors 
include optical (SPRi [137], [138], SERS [139]), electrochemical (nanowire [140]), and 
mechanical (QCM [141] and micro cantilever [142], [143]) immunosensors. Surface 
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plasmon resonance imaging (SPRi) Although planner array immunosensors are well-
developed, and some of them are commercially available [144], as discussed previously, 
the use of optical immunosensor chips are time consuming in setting up, difficult to 
integrate onto a sensor chip, and require expensive readers and skilled personnel. In 
comparison, microparticles encoding methods have many advantages including large 
multiplexed capacity, large surface area to volume ratio and easy-to-use. 
 
2.2.2 Suspension arrays 
 
Compared with planar arrays, suspension arrays based on microparticles have many 
advantages including easier surface modification, faster reaction kinetics, and better 
reproducibility [145] [146]. The microparticles encoding methods are classified as 
spectrometric, electronic, graphical, or physical methods [30]. A spectrometric encoding is 
based on the specific wave length of light or radiation. The fluorescent encoding is 
discussed in section 2.1.3 (see Figure 2.5). Other spectrometric encoding methods include 
colorimetric [147] [148], Raman tags [149][150], and Quantum dot encoding [151]. The 
disadvantages of spectrometric encoding include 1) limited multiplexed capacity; 2) low 
signal to noise ratio due to the interference between exaction signal and emission signal, 
and 3) bulky and expensive detection setups. As shown in Figure 2.5, a beam splitter and 
a detector are required for decoding each fluorescence color, which increase the complexity 
and cost of the flow cytometer. Among the electronic encoding methods, the 
radiofrequency (RF) tag encoding is able to provide >1012 types of labels, which represents 
a nearly unlimited multiplexing capability [36] [152]. This method is based on a radio-
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frequency identification technique. However, due to the large size of the RF chips (~8 mm 
× 1 mm × 1 mm), it is impossible to encode each microparticles with RF tags [126]. 
Graphical multiplexing approaches rely on patterning of various structures on the micro 
carriers, for example, striped rods [32], dot-pattern particles[33] or barcode micro/nano 
probes [30] [153], However, fabrication of these micro carriers is difficult, and detection 
of these graphical labels normally requires optical setups with high resolution and accurate 
alignment [126]. Physical encoding rely on encoding micro carriers with physical 
properties, such as size [155] [156], density, refractive index [156], shape [157], and 
composition [22]. However, most of these methods also rely on optical detection. The 
needs of bulky and expensive optics with high resolution and accurate alignments makes 
these methods impractical for on-site disease diagnosis, especially in a resource limited 
area. 
 
2.2.3 Multiplexed resistive pulse sensors 
 
There are two major strategies for multiplexed macromolecule detection. The first 
strategy is based on multichannel (multi-nano pores) approach. The second strategy is 
based on microparticle multiplexing. Both artificial and biological pores were used in the 
multiplexed detection studies [158][159][160]. For example, Osaki et al demonstrated a r-
Hemolysin nanopore array (8 channels) for molecular and DNA detection [159]. Bell et al 
demonstrated a multiple glass pores (16 channels) for DNA detection [160]. However, 
these approaches require a measurement setup for each channel, which limits their 
multiplexed capacity. Alternative electronic encoding methods were also achieved through 
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the uses of multi frequency excitation [161] and modification of micro channel structures 
[162]. However, for the multi frequency excitation method, a limited number of sensing 
channels can be added to the multichannel devices because of the narrow frequency range 
in which the resistive pulse sensors display a resistive behavior [163]. For the micro 
channel structure modification method, this method normally requires the use of a long 
sensing channel. However, a sensing channel with increased length has a low sensitivity, 
because the sensitivity is inversely proportional to the channel length. A decoding 
algorithm is also required, making this method time-consuming.  
Recently, Platt et al utilized a resistive pulse sensor to detect platelet-derived 
growth factor via DNA aptamer−nano rod aggregation [99]. In this method, different types 
of biomarker caused different shapes of aggregates (which are called “end-on-end” or 
“side-on” aggregates). The shape of the aggregates was distinguished based on the changes 
in resistive pulse height and width (transit time of particles). However, this method was 
unable to detect small changes in biomarker concentration because of the large deviations 
in resistive pulse signals at each biomarker concentration caused by the high aspect ratio 
of nano rods and aggregates formed with different shapes and orientations. Billinge et al 
reported a label free detection of biomarker using aptamers and tunable resistive pulse 
sensor [164] [165]. In their approach, the particle rate, defined as the counts of particles 
passing through a tunable pore per minute, was used as an indicator of target protein 
concentration. The particle rate decreased with an increase of protein concentration. 
However, the detection range of this method is affected by the particle concentration.  
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2.3 Micro resistive pulse immunosensors for cellular biomarkers detection 
 
Polymerase chain reaction (PCR) and immunoassay are two major methods for 
cellular biomarker detection [37]. Although a PCR-based sensor chip has a high sensitivity, 
it requires a long reaction time or a multi-step sample preparation procedures including cell 
lysis and enrichment steps [39]. The PCR-based biosensor chip is also complicated because 
of the on-chip temperature control for thermocycling and on-chip cell lysis [38] [39]. For 
an immunosensor, cellular biomarker detection is based on the specific binding between 
receptors on the surface of the cells and antibody immobilized on a solid surface. This 
binding event is then transduced to a detectable electrical or optical signal [9] [38], and 
detected through either labeling methods (fluorescence [166], luminescence [167], 
colorimetric [168] or magnetic particle [169]) or label-free methods (SPR [170], QCM 
[170]). 
Recent studies have also utilized resistive pulse immunosensors for cellular 
biomarker detection based on two strategies [171], [172]. The first strategy is to use an 
antibody functionalized sensing channel. The transit-time increase is used as an indicator 
of a target cell:  when a target cell passes the sensing channel, the transit-time was larger 
than that of a non-target cell due to the specific interaction between surface markers on a 
target cell and capture antibody coated on the sensing channel. The second strategy is to 
use an antibody functionalized capture chamber. Resistive pulse sensors were used to 
monitor the count of target cells captured in this chamber in order to measure the 
concentration of the target cells. Carbonaro et al demonstrated device based on transit-time 
differentiation for CD34 surface marker detection [171]. The sensing channel of this device 
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was immobilized with CD34 antibody. They proved that a target cell with CD34 surface 
marker has a larger transit-time than for the non-target cells (without the CD34 surface 
marker). However, the transit-time is dependent on the flow velocity, the sensing channel 
structure and off-axis effect [173]. Their results showed that the transit-time of target cells 
had a large variation and overlapped with the transit-time distribution of non-target cells. 
Thus, a transit-time modeling algorithm is required to further differentiate target cells from 
non-target cells. To further expand the performance of a transit-time differentiation based 
device and achieve a multiplexed detection, Karthik et al demonstrated a node-pore 
resistive pulse sensor which was able to simultaneously detect a single cell with up to five 
surface markers [174]. The sensing channel of this device was divided into five segments. 
Each segment was functionalized with one type of antibody. As a cell transits through the 
sensing channel (five segments in series), it will generate a resistive pulse consisting of 
five sub-pulses. The width of each sub-pulse represents the transit-time of a cell through 
one segment. By using this five-segment sensing channel, five surface biomarkers can be 
identified in a single test. However, there are two issues limiting the performance of this 
device. First, the increased length of the sensing channel not only increases the flow 
resistance, but also reduces the throughput of this device. Secondly, a long sensing channel 
has a low sensitivity, because the sensitivity is inversely proportional to the length of the 
sensing channel. 
In addition to transit-time based strategy, Douglas et al demonstrated a resistive 
pulse sensor for detection and identification of bacterial based on the capture chamber 
modification. In order to capture E.coli, the capture chamber of this device was 
functionalized with anti- E.coli antibody. The captured E.coli increased the resistance of 
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the capture chamber, which was used as an indicator of E.coli concentration. However, 
there are two drawbacks of this device. Firstly, the detection of E.coli was achieved through 
the bulk measurement of the chamber resistance. This device is unable to count each 
individual E.coli, and is also unable to provide the accurate concentration of the E.coli. 
Secondly, the large capture chamber with large resistance reduces the sensitivity of the 
resistive pulse sensor. Because a detectable resistance change requires a large amount of 
E.coli captured in the chamber. Thus, each test took a long time to complete. In order to 
provide the accurate count of target cells, one alternative option is to use two pair of 
resistive pulse sensors to measure and count cells entering and exiting the capture chamber. 
Nicholas et al demonstrated a differential counter for CD4 T lymphocyte detection [172]. 
The capture chamber of this device was functionalized with CD4 antibody. Two resistive 
pulse sensors were located at the entrance and the exit of the capture chamber in order to 
count the CD4 cells captured in the chamber. The resistive pulse sensors detected target 
cells based on the surface modification of sensing channels or capture chambers. However, 
maintaining the function of surface modification for a long period of time or reproducing 
the surface antibody coverage to reuse the sensor are difficult [37] [175]. In particular, 
regenerating the surface modification (surface antibody coverage) in a microchannel is a 
significant challenge [37] [175]. It is worth mentioning that microparticles coating inside 
of a microchannel via an external magnetic field can significantly reduce the difficulties in 
surface modification of immunosensor chips [31]. For example, Kralj et al demonstrated a 
simple packed bed device for circulating tumor cells (CTCs) capture [176]. Avidin-
functionalized microparticles were constrained in the microfluidic device by a weir 
structure and used to capture human breast cancer cells labeled with Biotinylated anti-
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EpCAM. Their results shows this device had a capture efficiency up to 70%. There are 
several disadvantages of this device, firstly, this device requires the labeling of target cells, 
which increases the assay steps. Secondly, the optical detection is time-consuming and 
requires bulk and complicate setups. 
It is worth mentioning that a resistive pulse sensor is also able to identify cells 
according to other properties including size [177][178][179], dielectric properties [180] 
[181] [182][183], and mechanical properties [184]–[186]. For example, circulating tumor 
cells (CTCs) normally have larger size than other blood cells [177], a micro resistive pulse 
sensor was used to differentiate model CTCs according their size [177]. Another example 
is the complete blood count (CBC) test. CBC test is used to detect a wide range of blood 
disorders, including anemia, infection and blood cancers. The analysis time is critical in 
CBC test [187]. Compared with traditional electronic particle counter, a micro resistive 
pulse sensor is able to rapid analysis blood sample with less sample consumption [187]. 
The mechanical property, especially the deformability, is associated with a range of 
diseases. For example, the deformability of red blood cells (RBCs) is related to severity of 
malaria [188]. Recent studies utilized micro resistive pulse sensor to evaluate the 
deformability of RBCs and monitor treatment of the of the malaria [189] [190]. Despite 
the promises, simply using the resistive pulses to detect cells has low specificity, i.e., it is 
very likely the two type of cells have size and deformability overlapping in a real sample 
with unknown contents. 
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2.4 Summery 
 
Immunosensors for macromolecule and cellular biomarker detection have been 
reviewed in this chapter in three aspects: label-free immunosensors, multiplexed 
immunosensors and resistive pulse sensor chips for cellular biomarker detection. A label-
free immunosensor chip is preferred for macromolecule detection for two major reasons. 
Firstly, a label-free immunosensor has a minimum number of assay steps without labeling 
of the detection antibody; secondly, the chemical labeling process may reduce the binding 
affinity of the capture antibody [25] [26]. Based on the types of detection signals, all-
electronic detection is preferred because the electronic components are easy to integrate on 
a sensor chip, and easy to use. Immunoaggregation assay is a label-free technique which is 
able to quantitatively detect macromolecule concentration. However, most of the current 
studies of immunoaggregation assays rely on optical detection. A resistive pulse sensor 
chip is highly sensitive to size change. Thus, the combination of immunoaggregation assay 
and resistive pulse sensing is a promising approach for macromolecule biomarker detection. 
Another important function of immunosensors is multiplexed detection capability. 
Compared with planar arrays, microparticles with a large surface area to volume ratio 
enable a high efficiency of interaction between target macromolecule and the capture 
antibody immobilized on the microparticles’ surface. However, most microparticles based 
encoding methods rely on optical detection. It is worth mentioning that it is feasible to use 
micro resistive pulse sensors for multiplexed detection. The microparticles can be encoded 
with physical properties such as size and the transit time through the resistive pulse sensor. 
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The size encoding method is more reliable because the transit time is also affected by the 
flow rate and microchannel geometry. 
The restive pulse sensor chip is also able to detect cellular biomarkers based on the 
interactions between receptors on the cell surface and the capture antibody coated on the 
microchannel. For immunosensor chips, maintaining the function of surface 
immobilization and regenerating the surface activities to reuse the sensor are difficult. The 
use of microparticles can significant reduce the difficulty in surface modification of 
immunosensor chips. 
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CHAPTER III 
DEMONSTRATION OF MICRO RESISTIVE PULSE IMMUNOAGGREGATION 
SENSOR 
 
 
 
3.1 Design concept and sensing principle 
 
 
Figure 3.1 Schematic of the immunoaggregation assay mechanism. Target biomarkers 
and antibody functionalized microparticles (Ab-MP) are mixed to form aggregates, which 
are detected by a micro resistive pulse sensor (reproduced with permission from Yu Han 
et al [1]. Copyright 2014 American Chemical Society) 
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In this chapter, I will present a single channel micro resistive pulse 
immunoaggregation sensor for biomarker detection. Figure 3.1 illustrates the 
immunoaggregation assay mechanism. The immunoaggregation assay consists of two 
major steps: firstly, biotinylated polyclonal antibody (Ab) conjugate with streptavidin 
coated microparticles (MPs) through streptavidin-biotin interaction to form the antibody 
functionalized microparticles (Ab-MPs). Then, Ab-MPs are mixed with a sample 
containing the target biomarkers. The specific binding between target biomarker and the 
polyclonal Ab on Ab-MPs triggers the aggregation of Ab-MPs; secondly, formed Ab-MP 
aggregates are detected by a micro resistive pulse sensor. When each particle passes 
through the sensing channel, it generates a resistive pulse between the pair of electrodes. 
The amplitude of the resistive pulse is proportional to the volume of the particle [145] [146]. 
The volume fraction of Ab-MP aggregates to all detected particles represents the level of 
the biomarker concentration.  
The advantages of this approach are multiple. Firstly, the immunoaggregation does 
not require the labeling of fluorescence or enzyme labels, and reduces the assay steps. 
Secondly, instead of direct detection of nano sized macromolecule, the detection of micro 
sized aggregates significantly amplifies the resistive pulse signal and eliminates the 
difficulties in fabrication of nano size sensing channels; thirdly, the use of micro sized 
sensing channel also increases the throughput of the immunoassay. 
 
3.2 Fabrication and calibration of the micro resistive pulse sensor 
 
The micro resistive pulse sensor was fabricated using standard photolithography 
and calibrated with standard microparticles.  
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3.2.1 Device fabrication 
 
 
Figure 3.2 (a) Schematic of the micro resistive pulse sensor; (b) microscopy 
image of sensing channel, and on-chip filter. (reproduced in part with permission from Yu 
Han et al [1]. Copyright 2014 American Chemical Society) 
 
As shown in Figure 3.2, the micro resistive pulse sensor consists of four parts: 1) a 
sensing channel with a width of 10 µm and a length of 30 µm to detect aggregates; 2) an 
on-chip filter with a pore width of 10 µm; 3) a pair of Ag/AgCl electrodes to measure the 
resistive pulses; and 4) inlet and outlet reservoirs (see Figure 3.2 (a)). It is worth mentioning 
here that if Ab-MPs are on a micro scale (a few microns), most aggregates are Ab-MP 
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doublets, which has also be shown in [27]. Thus most aggregates can pass through the 10 
× 10 µm filter. The micro resistive pulse sensor was fabricated using two-step 
photolithography. As shown in Figure 3.3. 
 
 
Figure 3.3 Fabrication process of the two-layer SU8 mold and the micro resistive 
pulse sensor 
 
The fabrication process of the two-layer SU8 mold and the micro resistive pulse 
sensor are shown in Figure 3.3. Firstly, a 10 µm thick SU8-5 layer was spin coated on a 
silicon wafer followed by a photolithograph step to define the pattern of the sensing 
channel and the filter; then the second layer of SU8-2025 (40 µm thick) was spin coated 
on top of the first layer to fabricate the reservoirs. Next, polydimethylsiloxane (PDMS) 
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was poured onto the two-layer SU8 mold, degassed and cured to form the microchannel. 
Inlet and outlet holes were punched to load and unload the sample. Two holes located on 
each side of the sensing channels were punched on the PDMS slab for insertion of the 
inlet/outlet tubing and a pair of Ag/AgCl electrodes. Finally, the PDMS channel was 
bonded to a glass slide via plasma treatment, and a pair of Ag/AgCl electrodes were 
inserted in the punched electrode holes to make the final device. 
 
 
 
Figure 3.4 Picture of the micro resistive pulse sensor with fluidic connections and 
a pair of Ag/AgCl electrodes (black and red wires in the picture) 
 
 
The fluidic connections are shown in Figure 3.4. The black and red wires were 
connected with Ag/AgCl electrodes, as shown in Figure 3.2 (a). The #1 and #6 tubing were 
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connected to the outlet reservoir and inlet reservoir, respectively. The other tubing were 
only used for cleaning purpose after each test. 
 
3.2.2 Calibration 
 
 
Figure 3.5 Measurement circuit for the micro resistive pulse sensor 
 
The measurement circuit for the resistive pulse sensor chip is shown in Figure 3.5. 
The micro resistive pulse sensor is modeled as a variable resistor Rc; Resistors R2 = R3 = 
500 kΩ. A variable resistor R1 ranging from 500 kΩ to 1 MΩ was set to match Rc. The 
gain of the differential amplifier, AD620, was programmed to be 50 using an external gain 
resistor RG = 1 kΩ. The input DC voltage, Vin = 2.4 V, was provided by a function generator 
(33220A, Agilent). The output signal was recorded by a data acquisition card (NI USB-
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6251, National Instruments) at a sampling rate of 1 MHz. Finally, a custom peak detection 
algorithm (Matlab, MathWorks) was used to count the resistive pulses and back calculate 
the particle size. 
 
 
Figure 3.6 Typical resistive pulses caused by particle passages. Each pulse represents one 
particle passing through the sensing channel. Small and large pulses represent 2.80 µm 
and 5.00 µm MPs 
 
Figure 3.6 shows the typical relative pulse caused by the passage of MPs. Each 
pulse represents one particle passing through the sensing channel. The amplitude of each 
pulse is proportional to the volume of the particle. Small and large pulses represent 2.80 
µm and 5.00 µm MPs, respectively. The particle sizes were back calculated using equation 
3.1 [191] [109]: 
       3322223 112 DdFLDLDLDdRR 



        (3.1) 
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where R is the resistance of the sensing channel, d is the diameter of the particle, D and L 
are the characteristic diameter and the length of the rectangular sensing channel and F is 
the correction factor. In our design, D was calculated to be 11.29 µm using D = (4·A/π)1/2, 
where A is the cross-sectional area of the sensing channel. F was taken to be 1.0 [109]. 
 
  
Figure 3.7 Calibration of sizing and counting performance of the resistive pulse sensor. 
(a) 2.80 µm and 5.00 µm MPs were used for the sizing calibration; (b) 2.80 µm MP with 
four concentrations were used for the counting calibration 
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Two kinds of MP were used to calibrate the counting and sizing performances of 
the resistive pulse sensor. The diameters of MPs are 2.80 µm (Dynabeads M-280, Life 
Technologies, USA) and 5.00 µm (79633 FLUKA, Sigma Aldrich). The measured sizes, 
which were back calculated from the resistive pulses using equation (3.1), were 2.80 ± 0.16 
µm and 4.91 ± 0.37 µm, as shown in Figure 3.7 (a). The sizing error of the micro resistive 
pulse sensor was less than 2%. For the concentration calibration, 2.80 µm MPs with four 
concentrations of 500 count/µL, 1000 count/µL, 2000 count/µL and 4000 count/µL were 
tested separately. The concentration was calculated by dividing the number of particles 
(resistive pulses) by the volume of the flow within the same time duration. As shown in 
Figure 3.7(b), the measured concentrations were 497 ± 28 count/µL, 960 ± 70 count/µL, 
2025 ± 138 count/µL and 3657 ± 240 count/µL, which are in good agreement with the 
actual MP concentrations (the counting error was less than 9%.).  
 
3.3 Study of a model biomarker immunoaggregation assay 
 
To prove that the presence of a target biomarker is able to trigger the aggregation 
of antibody functionalized MPs, goat anti-rabbit IgG, as a model biomarker, was employed 
in this section. The concentration of goat anti-rabbit IgG ranged from 16.0 to 320.0 ng/mL. 
To prepare antibody functionalized MPs (Ab-MPs), the biotinylated rabbit anti-goat IgG 
antibody (Ab) were conjugated to 2.80 µm MPs (MP, Dynabeads M280, Life Technologies, 
USA). The details of sample preparation were reported in our previous paper [1]. The Ab-
MPs concentration was 1.74×103 count/µL. At each test, 100.0 µL of goat anti-rabbit IgG 
was mixed with 100.0 µL of Ab1-MP1s for 30 mins to form the aggregates. The aggregates 
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were then driven through the micro resistive pulse sensor with a syringe pump (KDS 
Legato 270, KD Scientific) at flow rate of 100.0 µL/hr. It is worth mentioning here at 
current flow rate, the typical particle transit time was  about 0.1 ms, and about 100 data 
points were acquired to ensure the detection of a particle passage. 
 
 
Figure 3.8 The optical image of singlet Ab-MPs and Ab-MP aggregates at Ab-MPs 
concentration of 1.74×103 count/µL and the goat anti-rabbit IgG concentration of 160 
ng/mL 
 
Figure 3.8 shows the optical image of an Ab-MPs singlet and formed Ab-MP 
aggregates. The microscopy image proved the formation of immunoaggregates. As 
discussed earlier, the volume fraction of immunoaggregates, defined as the volume ratio of 
aggregates to all detected MPs, represents the levels of goat anti-rabbit IgG concentration. 
Next, the micro resistive pulse sensor was used to detect a large population of 
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immunoaggregates in order to accurately calculate the volume fraction. It is worth 
mentioning here that in a resource limited area, examination of aggregates under a light 
microscope is an alternative solution for immunoaggregation assays with drawbacks such 
as labor intensive and low accuracy. To prove the micro resistive pulse sensor is able to 
differentiate singlet Ab-MPs, doublet Ab-MPs and triplet Ab-MPs. The measured resistive 
pulses are shown in Figure 3.9. 
 
 
Figure 3.9 Relative resistive pulses caused by Ab-MP singlets, Ab-MP doublets and Ab-
MP triplets at Ab-MPs concentration of 1.74×103 count/µL, and the goat anti-rabbit IgG 
concentration of 160 ng/mL 
 
As discussed previously, accurate measurement of Ab-MP doublets can improve 
the sensitivity of immunoaggregation assays [102]. Figure 3.9 shows the clear difference 
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between Ab-MP singlets and two types of Ab-MP aggregates, this proves that the micro 
resistive pulse sensor chip is very sensitive to the size change compared with other optical 
sizing methods [51], [101]. Although we observed aggregates formed by more than three 
Ab-MPs under the light microscope, the small amount of aggregate was unable to represent 
the real volume fraction of aggregates. This also proves that a micro resistive pulse sensor, 
which is able to detect a large number of particles in a short time, has a higher accuracy 
than optical detection.  
 
 
Figure 3.10 Size and count distribution of Ab-MP at goat anti-rabbit IgG concentration of 
160 ng/mL. The volume fractions of aggregates was 40.3% 
 
Figure 3.10 shows the aggregate size distribution at a biomarker concentration of 
160 ng/mL. From Figure 3.10, the number of aggregates with more than three Ab-MPs was 
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very small. This proves that 1) the filter has a minor effect in blocking Ab-MP aggregates; 
and 2) the sensing channel with 10 × 10 µm cross section is suitable for 2.80 µm Ab-MP 
aggregate detection. In the above tests, a total of 16.2 × 103 particles were detected in less 
than 15 mins. To prove the volume fraction of aggregates represents the level of biomarker 
concentration, similar experiments were conducted with goat anti-rabbit IgG 
concentrations ranging from 16.0 to 320 ng/mL, while the Ab-MPs concentration (1.74 × 
103 count/µL) was kept constant. Each goat anti-rabbit IgG concentration was repeated five 
times to ensure accuracy. A control experiment was also conducted to evaluate nonspecific 
aggregation. Without adding goat anti-rabbit IgG to the Ab-MPs solution, the volume 
fraction of nonspecific aggregation was 11.0 ± 2.6 %. 
 
 
Figure 3.11 Volume fraction of Ab-MP aggregates as a function of goat anti-rabbit IgG 
concentrations ranging from 16.0 to 320 ng/mL 
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As shown in Figure 3.11, as the goat anti-rabbit IgG concentration increased from 
16.0 to 320 ng/mL, the aggregation ratio was increased from 10.9 to 40.3%. Note that at a 
high biomarker concentration > 320 ng/mL, the biomarkers occupied all the binding sites 
of the antibody for forming the aggregates; hence the volume fraction started to drop. The 
above test results demonstrated the feasibility of the immunoaggregation assay based on 
the micro resistive pulse sensor for sensitive biomarker detection. 
 
3.4 Summery 
 
The design concept and sensing principle of the immunoaggregation assay and 
micro resistive pulse sensor has been demonstrated in this Chapter. The goat anti-rabbit 
IgG, as a model biomarker, successfully caused the immunoaggregation of rabbit anti-goat 
IgG antibody factionalized MPs. A detection range from 16.0 to 160 ng/mL was achieved. 
The volume fraction of immunoaggregation increases with an increase in biomarker 
concentration. However, at high biomarker concentrations, the saturation of the binding 
sites prevents the formation of immunoaggregates. The above tests showed that the 
immunoaggregation assay performed with a micro resistive pulse sensor is able to 
quantitatively detect biomarker concentrations. 
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CHAPTER IV 
HUMAN FERRITIN IMMUNOAGGREGATION ASSAY 
 
 
 
4.1 Study of human ferritin immunoaggregation assay 
 
In Chapter III, the design concept and sensing principle of the micro resistive pulse 
immunoaggregation sensor were proved using goat anti-rabbit IgG as a model biomarker. 
In this chapter, the micro resistive immunoaggregation sensor was applied to human ferritin 
detection. Ferritins are a class of iron storage proteins and they are widely distributed in 
vertebrates, invertebrates, plants, fungi and bacteria. For humans, an increase in iron levels 
can promote the growth of a wide variety of tumors and infectious microorganisms [1]. 
Ferritin measurement is considered the most reliable method for the evaluation of iron 
stores in serum [193]. 
To prepare anti human ferritin antibody functionalized MPs (Ab-MPs), 
streptavidin-functionalized magnetic MP were conjugated with biotinylated anti ferritin 
antibody (Ab, US 152 Biological, USA) through streptavidin-biotin binding. Three Ab-MP 
concentrations were prepared which were 0.880 × 103, 3.50 × 103 and 14.0 × 103 count/µL. 
Human ferritin (US Biological, 164 USA) concentrations ranged from 0.104 to 416 ng/mL 
At each test, 333.4 μL of  Ab-MP  solution  was mixed with 166.7 μL  of  human  ferritin 
solution at different concentrations for 30 min in a thermal mixer at a speed of 650 rpm at 
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room temperature. Then, the sample solutions were loaded into the micro resistive pulse 
immunoaggregation sensor using a syringe pump (KDS Legato 270, KD Scientific) at flow 
rate of 80 μL/hr. The measurement setup shown in Figure 3.5 was used in this test.  
 
 
Figure 4.1 The microscopy image of Ab-MP aggregates formed at human ferritin 
concentration of 41.6 ng/mL and Ab-MP concentrations of 3.50 × 103 count/μL 
 
The formation of immunoaggregates were confirmed under the light microscope. 
Figure 4.1 shows the immunoaggregates formed by Ab-MPs at human ferritin 
concentration of 41.6 ng/mL and Ab-MP concentration of 3.50×103 count/μL. The counts 
and size distributions of Ab-MP aggregates were measured by the micro resistive pulse 
sensor and plotted in Figure 4.2. 
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Figure 4.2 Counts and size distribution of Ab-MP singlets and aggregates at human 
ferritin concentration of 41.6 ng/mL and Ab-MP concentrations of 3.50 × 103 count/μL 
 
Figure 4.2 shows the counts and size distributions of Ab-MP aggregates at a ferritin 
concentration of 41.6 ng/mL. From left to right, three peaks centered at 2.80 ± 0.21 µm, 
3.50 ± 0.19 µm and 3.98 ± 0.12 µm represent the Ab-MP singlets, Ab-MP doublets and 
Ab-MP triplets, as marked in Figure 4.2. The calculated equivalent spherical diameter 
(ESD) of Ab-MP doublets and triplets are 3.53 µm and 4.04 µm, respectively, which 
matched well with the measured results. It is worth mentioning here that the volume 
fraction of aggregates formed by more than three Ab-MPs compared to all 
aggregates/particles was less than 1%, which can barely be seen in Figure 4.2. The narrow 
size distribution of aggregates may provide a higher multiplexing capability when the 
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particle size is used as an encoding property. Because the detection limit of the 
immunoaggregation method is mainly controlled by nonspecific aggregation, Ab-MP 
solution without any human ferritin was used to evaluate nonspecific aggregation, as shown 
in Figure 4.3. 
 
 
Figure 4.3 Counts and size distribution of Ab-MP nonspecific aggregation at Ab-MP 
concentration of 3.50 × 103 count/μL 
 
Figure 4.3 shows counts and size distribution of Ab-MP nonspecific aggregation. 
When the Ab-MP concentration is 3.50 × 103 count/μL, the volume fraction of nonspecific 
Ab-MP aggregates is 0.051 ± 0.006. Next, similar tests were conducted at various human 
ferritin concentrations ranging from 1.04 ng/mL to 208 ng/mL. The Ab-MP were kept at a 
constant concentration of 3.50 × 103 count/μL. The counts of singlet Ab-MP and Ab-MP 
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aggregates were obtained using the same procedure. After the nonspecific aggregates were 
subtracted from the measured immunoaggregates, the volume fractions of Ab-MP 
aggregates at different ferritin concentrations were plotted in Figure 4.4, as a function of 
the ferritin concentration. To ensure repeatability, at each ferritin concentration, 10 
immunoaggregation samples were prepared and measured. 
 
 
Figure 4.4 The volume fraction of Ab-MP aggregates at various human ferritin 
concentrations ranging from 1.04 to 208.0 ng/mL. The Ab-MP concentration was 3.50 × 
103 count/μL 
 
As shown in Figure 4.4, the measurement curve in the range from 1.0 ng/mL to 
62.4 ng/mL can be fitted with a logistic function: 
126.21 )935.15(1
358.0
034.0)(


x
xf                               (4.1) 
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where the coefficient of determination (R2) of the fitted curve is 0.998. As shown in Figure 
4.4, the volume fraction of aggregates, f1, increased with the increase of ferritin 
concentration, x, in the range from 1.04 ng/mL to 62.4 ng/mL. The maximum volume 
fraction (35.4%) occurred at 62.4 ng/mL. Above 62.4 ng/mL, f1 reduced with the increase 
in the ferritin concentration. This is because higher ferritins concentrations saturated the 
binding sites on the Ab-MPs and prevented the formation of Ab-MP aggregates. 
Disease related biomarkers are often isolated from a complexing media such as 
blood, urine,  etc. [193]. One long-standing challenge for biomarker detection in a complex 
media is the nonspecific binding between non-target molecules to capture probes. In order 
to prove that nonspecific binding has a negligible effect on the human ferritin 
immunoaggregation assay, 10% fetal bovine serum (FBS, Sigma-Aldrich, USA) was used 
as a complex media to mimic a real disease diagnosis condition. First, in order to evaluate 
the nonspecific aggregation, samples containing 10% FBS without any human ferritin were 
mixed with 3.50 × 103 count/μL of Ab-MPs solution, then tested by the micro resistive 
pulse sensor. To ensure accuracy, five samples were prepared and tested. The volume 
fraction of nonspecific aggregates was 0.054 ± 0.011. As discussed previously, without 
adding 10% FBS, the volume fraction of nonspecific aggregates was 0.051 ± 0.006. Thus, 
the 10% FBS has a negligible effect on nonspecific aggregates. To prove the micro resistive 
pulse sensor is able to quantitatively detect human ferritin in a complex media, samples 
containing 10% FBS and human ferritin ranging from 0.104 ng/mL to 104 ng/mL was 
mixed with 3.50 × 103 count/μL of Ab-MP solution, then tested by the micro resistive pulse 
sensor. To ensure accuracy, at each human ferritin concentration, 10 samples were prepared 
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and tested. The relationships between human ferritin concentration and volume fraction of 
aggregates is shown in Figure 4.5. 
 
 
Figure 4.5 The volume fraction of Ab-MP aggregates as a function of human ferritin 
concentrations ranging from 0.104 to 104 ng/mL. The Ab-MPs concentration was 3.50 × 
103 count/μL 
 
The measurement curve in the range from 0.104 ng/mL to 62.4 ng/mL in Figure 4.5 
can be fitted with a logistic function: 
1.1832 )12.964(1
356.0
009.0)(
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x
xf                                   (4.2) 
The coefficient of determination (R2) of the fitted curve is 0.999. As shown in Figure 3.14, 
the volume fraction of aggregates, f2, increased with an increase of ferritin concentration, 
x, in the range of 0.104 ng/mL to 62.4 ng/mL; the maximum volume fraction (31.1%) 
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occurred at 62.4 ng/mL. Without adding 10% FBS to the Ab-MP solution, the maximum 
volume fraction (35.4%) also occurred at 62.4 ng/mL, as shown in Figure 4.4. This 
indicates that the detection range is not affected by FBS. Hence the micro resistive pulse 
immunoaggregation sensor can be used for biomarker detection in complexed media. The 
limit of detection (LOD) is the smallest biomarker concentration that has a volume fraction 
of specific aggregation significantly larger than the volume fraction of nonspecific 
aggregation. The volume fraction of aggregates at the limit of detection (fLOD) is given by:  
𝑓𝐿𝑂𝐷 = 𝑓0 + 3 × 𝜎0                                                (4.3) 
where f0 is the volume fraction of nonspecific aggregates. σ0 is the standard deviation of 
the nonspecific aggregation. For the experiment shown in Figure 4.4, f0 = 5.1%, σ0 = 0.6%. 
Thus, fLOD = 6.9%. By using equation 4.2, the detection limit of human ferritin is 0.6 ng/mL. 
Note that the volume fraction of nonspecific aggregates, 5.1%, was subtracted from fLOD 
before using equation 4.2.  
 
4.2 Tunable detection range with multiple microparticle concentrations 
 
It is hypothesized that the Ab-MPs concentration may affect the detection range 
because: 1) a higher Ab-MP concentration provides a larger total surface area and larger 
number of binding sites and hence is able to capture more biomarkers, which may result in 
a larger upper detection limit; 2) a lower concentration of Ab-MPs with limited binding 
sites is easily saturated, and hence may have a better detection resolution for detection of 
low concentration biomarkers. To prove this hypothesis, three Ab-MP concentrations 
(0.880 × 103, 3.50 × 103 and 14.0 × 103 count/µL.) were evaluated using human ferritin 
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with concertation ranging from 0.104 ng/mL to 416 ng/mL in 10% FBS. To ensure 
accuracy, at each human ferritin concentration, 10 samples were prepared and tested. The 
results are shown in Figure 3.15. It is worth mentioning here that, before this test, 10% 
FBS without human ferritin was mixed with three concentrations of Ab-MPs as negative 
controls to evaluate the nonspecific aggregation. At each Ab-MP concentration, the five 
negative controls were prepared and tested. Volume fractions of nonspecific aggregates for 
the negative controls were 0.045 ± 0.008, 0.054 ± 0.011 and 0.049 ± 0.002 for Ab-MP 
concentrations of 0.880 × 103, 3.50 × 103 and 14.0 × 103 count/µL, respectively, which 
were close to that in PBS at the concentration of 3.50 × 103 count/µL. The results proved 
that 1) Ab-MPs are stable in the complex medium, and 2) the change of Ab-MP 
concentrations has a negligible effect on nonspecific aggregation. 
 
 
Figure 4.6 The volume fraction of Ab-MP aggregates as functions of human ferritin 
concentrations ranging from 0.104 to 416 ng/mL 
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The three curves shown in Figure 4.6 were also fitted with logistic functions from 
0.104 ng/mL to the peak position. The R2 was greater than 0.998. For the three Ab-MP 
concentrations, 0.880 × 103 (black line), 3.50 × 103 (red line) and 14.0 × 103 count/µL (blue 
line), the detection ranges were 0.104 to 10.4 ng/mL, 0.104 to 62.4 ng/mL and 0.104 to 
208 ng/mL, respectively. This proves that the use of a higher Ab-MP concentration is able 
to increase the upper detection limit for detection of high concentration biomarkers. In 
comparison, the detection range shifted to lower concentrations when a low Ab-MP 
concentration was used, because low concentration Ab-MPs only have limited binding sites 
and are easily saturated. The maximum volume fractions of aggregates were 29.7%, 31.1% 
and 31.2% for Ab-MP concentrations of 0.880 × 103, 3.50 × 103 and 14.0 × 103 count/µL. 
The maximum volume fractions of aggregates of these three Ab-MP concentrations were 
close to each other. Thus, with a reduced detection range, a lower Ab-MP concentration 
was more sensitive to a lower biomarker concentration, as shown in Figure 4.6. For 
example, for a ferritin concentration ranging from 0.104 ng/mL to 10.0 ng/mL, the use of 
a low Ab-MP concentration (black curves) was able to differentiate the difference in ferritin 
concentration, while the use of high Ab-MP (red and blue curves) concentrations was 
unable to. Thus, the sensitivity and detection range of the immunoaggregation assay are 
tunable by adjusting Ab-MP concentrations. Another alternative method to detect the 
higher biomarker concentration is to serial dilute the sample and detect using lower 
microparticle concentration. It is worth mentioning here, the dilution process has a 
negligible effect on the immunoaggregation. 
Compared with currently available ELISA kits, as listed in Table 3.1, the micro 
resistive pulse immunoaggregation sensor has a low limit of detection, at 0.60 ng/mL. To 
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further decrease the lower detectable biomarker concentration, one possible solution is to 
use aptamer functionalized micro particles with higher binding affinity to the given 
biomarker, which is expected to improve the volume fraction at lower biomarker 
concentration. The lower and upper detection limits can be extended by decreasing and 
increasing the concentrations of Ab-MPs. Without any labeling process, the 
immunoaggregation assay has less assay steps, and takes less than 1 hour. In comparison, 
the conventional ELISA method takes several hours to a day to complete. The estimated 
cost of an immunoaggregation assay (~$10), is comparable with the cost of a commercial 
ELISA test. However, the microplate photometer for ELISA costs a few thousand dollars, 
while a resistive pulse sensor chip only requires a portable and cost-effective electronic 
data acquisition device, which costs less than $100.  
 
Table 3.1 Commercial available human ferritin ELSA kits 
Products 
Detection limit 
(ng/ml) 
Vendors 
ab108837 1.6 Abcam 
25 FERHU E01 5.0 ALPCO 
FER31-K01 6.0 Eagle Biosciences 
RCAN-F-4280R 7.5 BioVendor 
 
4.3 Summery 
 
In this Chapter, the micro resistive pulse sensor was used to detect human ferritin 
concentrations in a complex media. A detection range from 0.104 to 208 ng/mL was 
achieved. The lower limit of detection, 0.1 ng/mL, is lower than that of commercial ELISA 
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kits. The test results also indicated that antibody functionalized MPs were stable in 10% 
fetal bovine serum (FBS) and adding 10% FBS had a negligible effect of nonspecific 
aggregation. In addition, the detection range can be shifted to lower and higher biomarker 
concentrations by decreasing and increasing MP concentrations. 
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CHAPTER V 
MULTIPLEXED IMMUNOAGGREGATION ASSAY 
 
 
 
5.1 The design concept of the multiplexed immunoaggregation assay 
 
The studies shown in Chapters III and IV have shown that the micro resistive pulse 
immunoaggregation sensor is able to quantitatively detect biomarker with high sensitivity. 
Two types of macromolecule, goat anti-rabbit IgG and human ferritin, were detected 
separately. To detect multiple biomarkers simultaneously, a multiplexed 
immunoaggregation assay is studied in this Chapter, based on size and the magnetic 
properties of MPs. 
 
5.1.1 The design concept and sensing principle 
 
 
Figure 5.1 Schematic of the multiplexed immunoaggregation assay mechanism 
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Figure 5.1 shows the multiplexed immunoaggregation assay mechanism. Two 
types of Ab-MPs are used to detect two types of biomarker (BMs). Firstly, the sample 
solution containing two target biomarkers, BM1 and BM2, is mixed with the mixture of 
antibody functionalized MPs, Ab1-MP1 and Ab2-MP2. Ab1, immobilized on Ab1-MP1s 
is specific to the biomarker BM1. Thus, the presence of BM1 triggers the aggregation of 
Ab1-MP1s. The volume fraction of Ab1-MP1 aggregates to all detected Ab1-MP1s 
represents the concentration of BM1. Similarly, BM2 causes the aggregation of Ab2-MP2 
due to the specific binding between BM2 and Ab2, and the volume fraction of Ab2-MP2 
aggregation is indicative of BM2 concentration. The two-stage resistive pulse sensor (two-
stage RPS) is used to differentiate Ab1-MP1, Ab2-MP2 and their aggregates, as shown in 
Figure 5.2. 
 
  
Figure 5.2 Design concept of the two-stage resistive pulse sensor (two-stage RPS) for 
multiplexed immunoaggregation assay 
 
As shown in Figure 5.2, biomarker sample and Ab-MP mixture are mixed on the 
sensor chip in the inlet reservoir. The formed aggregates are driven through the two stage 
resistive pulse sensors (RPS) in series. The 1st RPS are used to detect the size and count of 
Ab1-MP1, Ab2-MP2 and their aggregates. The volume fraction of Ab-MP doublets is 
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indicative of biomarker concentration. For example, the volume fraction of Ab1-MP1 
doublets, which is defined as the ratio between the volume of formed Ab1-MP1 doublets 
and total volume of Ab1-MP1 singlets and doublets, is indicative of BM1 concentration. 
The volume fraction of Ab2-MP2 doublet is defined in the same way and is indicative of 
BM2 concentration. The diameter of Ab1-MP1 is appropriately selected to ensure that the 
Ab1-MP1 doublet is smaller than the Ab2-MP2 singlet. Thus, the 1st RPS is able to 
differentiate Ab1-MP1, Ab2-MP2 and their doublets according to their size, to further 
calculate the BM1 and BM2 concentrations. 
To further extend the multiplexed capability, Ab1-MP1, Ab2-MP2 and their 
doublets are differentiated according to their magnetic properties. Ab1-MP1 conjugated 
with Ab1 are non-magnetic particles while MP2 conjugated with Ab2 are magnetic 
particles. Ab2-MP2s and their aggregates can be captured in the capture chamber where an 
external magnetic field is applied. Hence only non-magnetic particles (Ab1-MP1s) and 
their aggregates are detected by the 2nd RPS, while the 1st RPS detects all particles and 
aggregates. The difference of aggregates measured by the 1st RPS and the 2nd RPS 
represents the magnetic particle aggregates, which are indicative of the concentration of 
BM2. Hence with the two stage resistive pulse sensing device, multiple biomarkers can be 
detected in terms of size and magnetic properties of the formed aggregates. 
 
5.1.2 Fabrication, measurement setup and test procedure 
 
Figure 5.3  shows the sensing channels and capture chamber of the two-stage 
RPS. The two-stage RPS consists of four parts. 
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Figure 5.3 Microscopic image of two-stage RPS. (a) 1st RPS; (b) capture chamber; (c) 2nd 
RPS; (d) image of the two-stage RPS with three Ag/AgCl electrodes and an external 
magnet 
 
Figure 5.3 (a-c) shows the sensing channels and capture chamber of the two-stage 
RPS. The two-stage RPS consists of: 1) two sensing channels with a width of 10 µm and a 
length of 30 µm to detect aggregates, 2) a capture chamber with width of 1 mm and a length 
of 15 mm to capture magnetic Ab2-MP2 aggregates, 3) inlet and outlet reservoirs, and 4) 
three Ag/AgCl electrodes to measure the resistive pulses (as shown in Figure 5.3(d)). A 
two-layer SU8 mold, consisting of patterns for the sensing channel (with a thickness of 10 
µm), capture chamber and reservoirs (with a thickness of 40 µm), was created by two-step 
photolithography. Two-step photolithography is discussed in section 3.1.1 (Figure 3.3). 
Two sizes of Ab-MPs were chosen for the multiplexed detection. They are rabbit anti-
mouse IgG antibody (Ab1) functionalized MPs (Ab1-MP1, average diameter of 2.00 µm, 
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non-magnetic MP, Polysciences, Inc., USA), and anti-human ferritin antibody (Ab2) 
functionalized MPs (Ab2-MP2, average diameter of 2.80 µm, magnetic MP,). The Ab-MPs 
were prepared using the same procedures as discussed in section 3.3. For each test, 166.7 
μL of biomarker sample and 333.4 μL of Ab-MP mixture were mixed on a thermal mixer 
for 30 mins, then 50.0 μL of the mixed sample was driven through the two-stage RPS at a 
flow rate of 20 µL/hr by a syringe pump (KDS Legato 270, KD Scientific). An external 
magnet (Grade N42, 3.2 mm × 3.2 mm × 3.2 mm, K&J Magnetics, Inc.) was used to capture 
the magnetic Ab2-MP2s in the capture chamber. The external magnet was placed 10 mm 
away from the 1st stage RPS, as shown in Figure 5.3. Using such a large distance reduces 
the possibility of magnetizing the magnetic MPs before they enter the 1st RPS. Magnetized 
MPs tend to form nonspecific aggregates, which will be counted as immunoaggregates and 
lead to errors in biomarker concentration measurement. 
 
 
Figure 5.4 Measurement setup and equivalent circuit of the two-stage RPS 
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The two-stage RPS are modeled as RC1 and RC2 in the circuit. Variable resistor R1, 
ranging from 500 kΩ to 1 MΩ, was used to adjust the difference between the two input 
voltages (V1 and V2) of the differential amplifier to zero at the beginning of each test. R2 
was set to 500 kΩ. The gain of the differential amplifier, AD620, was programmed to be 
50 using an external gain resistor RG = 1 kΩ. The output signal, Vout, was recorded at a 
sampling rate of 500 kHz. A typical output signal generated by the two-stage RPS is shown 
in Figure 5.5. 
 
 
Figure 5.5 Typical resistive pulses measured by the two-stage RPS. The positive and 
negative pulses represent the passages of Ab2-MP2s through the 1st RPS and 2nd RPS, 
respectively 
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The typical resistive pulses caused by the passages of Ab2-MP2s (2.80 µm in 
diameter) are shown in Figure 5.5. When a particle transits through the 1st RPS, it increases 
RC1 and leads to a positive pulse in the output signal, Vout. While the passage of a particle 
through the 2nd RPS generates a negative pulse in the output signal, Vout. From the output 
signal, the particle sizes were back calculated using equation 3.1. It is possible that particles 
pass through the two resistive pulse sensors at same time, which will lead to an incorrect 
count and incorrect concentration measurement. This issue can be overcome by taking two 
independent measurements of the two RPSs, using two pairs of electrodes. 
 
5.2 The relationship between volume fraction of Ab1-MP1 doublets and BM1 
concentrations 
 
The studies presented in this section have two purposes. The first purpose is to 
prove that the use of Ab1-MP1 is able to quantitatively detect BM1 concentration. Note 
that the relationship between Ab2-MP2 aggregates and BM2 concentration was studied in 
section 4.1. The second purpose is to study the concentration of Ab1-MP1 triplets. The 
calculated equivalent diameter of the Ab1-MP1 triplet is 2.88 µm, which overlaps with the 
Ab2-MP2 singlet. Thus, Ab1-MP1 triplet concentration should be small and have a 
negligible effect on the detection of Ab2-MP2 concentration. 
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Figure 5.6 Microscope image of formed Ab1-MP1 aggregation. The Ab1-MP1 
concentration is 5.80 × 103 counts/mL and BM1 concentration is 24.0 ng/mL 
 
Figure 5.6 shows the microscope image of the formed Ab1-MP1 aggregates. In this 
test, 166.7 µL of 24.0 ng/mL BM1 was mixed with 166.7 µL Ab1-MP1 solution for 30 
mins in the thermal mixer to from the aggregates. The concentration of Ab1-MP1 was 5.80 
× 103 counts/mL. Then the formed Ab1-MP1 aggregates were detected by a single channel 
RPS. The count and size distribution of Ab1-MP1 aggregates are shown in Figure 5.7. 
 
69 
 
 
Figure 5.7 Counts and size distribution of the formed Ab1-MP1 aggregation. The Ab1-
MP1 concentration is 5.80 × 103 counts/mL and BM1 concentration is 24.0 ng/mL 
 
Figure 5.7 shows the counts and size distribution of Ab1-MP1 aggregates. From 
left to right, two peaks centered at 2.04 ± 0.07 µm and 2.55 ± 0.09 µm represent singlet 
Ab1-MP1 and Ab1-MP1 doublets. The calculated equivalent spherical diameter (ESD) of 
Ab1-MP1 doublets is 2.52 µm, which agrees well with the measured result. The calculated 
volume fraction of Ab1-MP1 doublets is 27.2%. In order to evaluate the nonspecific 
aggregation of Ab1-MP1, five Ab1-MP1 solutions without added BM1 were prepared and 
tested. The volume fraction of Ab1-MP1 doublets caused by nonspecific aggregation was 
17.9 ± 0.4%. Next, similar tests were conducted at various BM1 concentrations ranging 
from 10.4 to 51.2 × 103 ng/mL, the Ab1-MP1s were kept constant at 5.80 × 103 counts/mL. 
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To ensure the repeatability, at each BM1 concentration, five samples were prepared and 
measured. 
 
 
Figure 5.8 The relationship between the volume fraction of Ab1-MP1 doublets and BM1 
concentrations. BM1 concentration ranged from 10.4 to 51.2 × 103 ng/mL, the Ab1-MP1s 
concentration was kept at 5.80 × 103 counts/mL 
 
As shown in Figure 5.8, the volume fraction of Ab1-MP1 doublets increases with 
the increased Ab1 concentration. A detection range from 10.4 to 51.2 × 103 ng/mL was 
achieved. This test proved that the use of Ab2-MP2 is able to quantitatively detect BM1s 
concentrations. The equivalent spherical diameter of the Ab2-MP2 triplet was 2.88 µm, 
which overlapped with the size of the Ab1-MP1 singlet (2.80 µm). This will cause false 
counts of Ab2-MP2 singlets. The counts of Ab1-MP1 triplets ranged from 154 to 500 
count/µL. In the next study (multiplexed detection with a mixture of Ab1-MP1 and Ab2-
MP2), the Ab2-MP2 concentration was chosen to be much higher than the Ab1-MP1 
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concentration (2.4 times) to ensure that the volume of Ab1-MP1 triplets is negligible 
compared with the total volume of Ab2-MP2s. 
 
5.3 Multiplexed detection of human ferritin and mouse anti-rabbit IgG 
 
A mixture consisting of Ab1-MP1 and Ab2-MP2 was used to detect BM1 (mouse 
anti-rabbit IgG) and BM2 (human ferritin) concentrations. Firstly, to confirm the formation 
of two types of aggregates, Ab-MP mixture containing 5.80 × 103 count/mL of Ab1-MP1 
and 1.40 × 103 count/mL of Ab2-MP2 were mixed in a sample containing 24.0 ng/mL of 
BM1 and 208 ng/mL of BM2. The formed aggregates are shown in Figure 5.9. 
 
 
Figure 5.9 Microscope image of formed Ab1-MP1 and Ab2-MP2 aggregates 
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Figure 5.9 confirmed the formation of Ab1-MP1 and Ab2-MP2 doublets. Next, the 
formed aggregates were detected by the two-stage RPS. As discussed previously, the 1st 
RPS was used to differentiate Ab1-MP1, Ab2-MP2 and their doublets according to their 
size, as shown in Figure 5.10. 
 
 
Figure 5.10 Count and size distribution of formed Ab1-MP1 and Ab2-MP2 aggregates 
 
Figure 5.10 shows the counts and size distributions of Ab1-MP1 and Ab2-MP2 
aggregates. From left to right, the first two peaks centered at 1.99 ± 0.06 µm and 2.50 ± 
0.09 µm represent the distribution of singlets and doublets of Ab1-MP1s. The measured 
diameters matched well with the calculated equivalent diameter of the Ab1-MP1 doublets, 
which is 2.52 µm. The third and fourth peaks centered at 2.87 ± 0.07 µm and 3.60 ± 0.11 
µm represent the singlets and doublets of Ab2-MP2s. The calculated equivalent diameter 
of Ab2-MP2s doublets is 3.53 µm, which also matches well with the measured result. The 
73 
 
results shown in Figure 5.10 demonstrated that the 1st-stage RPS is able to differentiate 
Ab1-MP1s and Ab2-MP2s probes and their doublets according to their size distribution. 
Next, to prove the volume fraction of Ab1-MP1s doublet, f1, can be correlated to the 
concentrations of BM1, similar tests were conducted at various BM1 concentrations 
ranging from 3.10 to 51.2 × 103 ng/mL, while BM2 concentration was kept a constant of 
41.6 ng/mL. For each BM1 concentration, five samples were prepared and tested. It worth 
mentioning that the nonspecific aggregation of Ab1-MP1s and Ab2-MP2s were evaluated 
before the test. The volume fraction of nonspecific doublets were 17.9 ± 0.4% and 5.3 ± 
0.5% for Ab1-MP1s and Ab2-MP2s, respectively. After subtracting the volume fraction of 
nonspecific doublets, volume fractions of Ab1-MP1s doublets as a function of the BM1 
concentrations were plotted in Figure. 5.11. 
 
 
Figure 5.11 Measured relationship between the concentrations of BM1 ranging from 3.10 
to 51.2 × 103 ng/mL and volume fraction of Ab1- MP1 doublet (f1) 
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The relationship between volume fraction of Ab1-MP1s doublets and BM1 ranging 
from 3.10 to 51.2 × 103 are shown in Figure 5.11 (black dots), which can be fitted with a 
4-parameter logistic function (dash curve): 
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The coefficient of determination (R2) of the fitted curve is 0.9883. From 3.10 to 51.2 × 103 
ng/mL, the volume fraction of Ab1-MP1s doublets, f1, increased with the increase of BM1 
concentration in the range of 3.10 ng/mL to 51.2 × 103 ng/mL. The maximum value, f1 = 
40.3%, was achieved at a BM1 concentration of 51.2 × 103 ng/mL. The solid line in Figure 
5.11 shows the volume fraction of Ab2-MP2 doublets. The average volume fraction of 
Ab2-MP2 doublets is 11.1 ± 2.0%. As shown in section 5.2, for an Ab1- MP1s 
concentration of 5.80×103 count/µL, the Ab1-MP1 triplets’ concentration ranged from 154 
to 500 count/µL. Hence if BM2 and Ab2-MP2 are added to the solution with a 
concentration of 1.40×104 count/µL to from aggregates, the volume fraction of AB1-MP1 
triplets to total volume of Ab2-MP2s and aggregates is estimated to range from 1.5% to 
3.8% at all BM1 concentrations. The value was 1.5% at a BM1 concentration of 24.0 
ng/mL. Hence the error caused by the size overlapping of Ab1-MP1s triplets and Ab2-MP2 
can be neglected.  
Next, we prove that the volume fraction of Ab2-MP2s doublets, f2, is correlated to 
the concentration of BM2. In this experiment, the concentration of BM2 was varied from 
5.20 ng/mL to 208 ng/mL; while BM1 concentration was kept constant at 24.0 ng/mL, as 
shown in Figure 5.12. The volume fraction of nonspecific Ab2- MP2 doublets was 5.3 ± 
0.5%. 
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Fig. 5.12 Measured relationship between the concentrations of BM2 ranging from 5.20 to 
208 ng/mL and volume fraction of Ab2- MP2 doublets (f2) 
 
The correlation between the volume fraction of Ab2-MP2 doublets and BM2 
ranging from 5.20 to 208 ng/mL was also fitted with a 4-parameter logistic curve (solid 
curve).  
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The coefficient of determination (R2) of the fitted curve is 0.9870. The volume 
fraction of Ab2-MP2s aggregates increased from 2.7 % to 33.1 % with an increase of BM2 
concentration in the range of 5.20 ng/mL to 208 ng/mL. With a fixed BM1 concentration 
of 24.0 ng/mL, the volume fraction error caused by the Ab1- MP1 triplets is estimated to 
be approximately 1.5%. Hence using the multiplexed immunoaggregation assay we can 
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confidently measure BM2 concentrations as low as 5.20 ng/mL. The maximum volume 
fraction (33.1%) occurred at 208 ng/mL. Above 208 ng/mL, the volume fraction f2 was 
reduced with an increase of BM2 concentration. This is because the high concentration of 
BM2 would saturate Ab2 on the surfaces of the Ab2-MP2s; hence the number of unreacted 
Ab2 on Ab2-MP2s is too low to cause aggregation. The measured average volume fraction 
of Ab1-MP1s doublets is 11.6 ± 1.4% for the constant BM1 concentration of 24.0 ng/mL. 
Using equation 5.1 and a BM1 concentration of 24.0 ng/mL, the calculated volume fraction 
of Ab1-MP1s doublets is 12.8%, which matched well with the measured value (11.6 ± 
1.4%). Using equation 2 and a BM2 concentration of 41.6 ng/mL, the calculated volume 
fraction of Ab2-MP2s is 11.3%, which also matched well with the measurement results in 
Fig. 5.11 (11.1 ± 2.0%). The results shown in Fig. 5.11 and 5.12 clearly demonstrate: 1) 
the volume fractions of Ab1-MP1s and Ab2-MP2s, are correlated to the concentrations of 
BM1 and BM2 in a mixture; 2) the 1st-stage RPS is capable of differentiating Ab1-MP1s 
and Ab2-MP2s singlets and their doublets according to their size difference. 
Next, experiments were conducted to prove that the two biomarkers (BM1 and 
BM2) can also be detected in terms of the magnetic properties of the aggregates. The 
magnetic Ab2-MP2 aggregates are correlated to the BM2, and the non-magnetic Ab1-MP1 
aggregates are correlated to the BM1. An external magnet was used to capture magnetic 
particles in the capture chamber while the non-magnetic particles were counted by the 2nd-
stage RPS. 
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Figure. 5.13 Counts of two types Ab1-MP1s and Ab2-MP2s and their aggregates 
measured by the two-stage RPS 
 
In order to prove that the external magnet is able to capture magnetic Ab2-MP2s 
and their aggregates with high efficiency, we compared the count and size distribution 
measured by the 1st and 2nd RPSs with the following experimental conditions: 1) the 
biomarker sample contained 208 ng/mL of BM2 without BM1; and 2) the mixture of Ab1-
MP1s and Ab2-MP2 was used at the same concentration as the previous experiments. The 
counts of different-sized particles are shown in Figure 5.13. The capture efficiency is 
calculated as a ratio of the difference in magnetic particle (magnetic Ab2-MP2 and its 
aggregates) counts between the 1st RPS and the 2nd RPS over all magnetic particle counts 
measured by the 1st RPS. From the measurements shown in Figure 5.13, the capture 
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efficiency was calculated to be great than 98.0%, which is high enough to ensure accurate 
counts of magnetic particles. 
Next, to prove that the 2nd RPS can accurately count and size the nonmagnetic Ab1-
MP1, the nonmagnetic Ab1-MP1 doublets measured by the 1st and 2nd RPS were compared 
with BM1 concentrations ranging from 3.10 to 51.2 × 103 ng/mL as shown in Figure 5.14. 
 
 
Figure 5.14 Comparison of the volume fraction of the nonmagnetic Ab1-MP1 doublets 
measured by the 1st and 2nd RPS, respectively. BM1 concentrations ranged from 3.10 to 
51.2 × 103 ng/mL 
 
The Figure 5.14 shows the volume fraction of nonmagnetic doublets measured by 
the 1st and 2nd RPS with a BM1 concentration ranging from 3.10 to 51.2 × 103 ng/mL. The 
volume fraction ratio measured by the 1st RPS and 2nd RPS match reasonably well in this 
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concentration range. For the BM1 concentrations ranging from 24.0 to 51.2 × 103 ng/mL, 
the measurement error ranges from 0.2% to 4.1%. One possible cause for this error is the 
nonspecific attachment of nonmagnetic Ab1-MP1s and their aggregates. This nonspecific 
attachment may also lead to larger errors (5.5 % to 7.3 %) at lower BM1 concentrations 
(3.10 ng/mL and 12.0 ng/mL). 
The lower detection limit of the multiplexed immunoaggregation assay is 3.10 
ng/mL and 5.20 ng/mL for BM1 and BM2, which are comparable to those of commercial 
ELISA kits (~6.0 ng/mL for BM1, and ~5.0 ng/mL for BM2). ). Three possible solutions 
to further expand the lower detection limit are: 1) use antibody with higher binding affinity, 
which will increase the volume fraction of aggregates at lower biomarker concentration, 2) 
use antifouling materials to avoid nonspecific aggregation, and 3) use various MP 
concentrations to adjust the detection range, as demonstrated in section 4.2. With the 
demonstration of the multiplexed immunoaggregation biomarker assay in terms of size and 
magnetic properties of Ab-MPs, if four types of Ab-MPs are used (2 different-sized 
magnetic Ab-MPs, and 2 different-sized non-magnetic Ab-MPs), four biomarkers can be 
detected using the two-stage RPS sensor: the 2nd stage RPS measures the concentration of 
the two biomarkers that trigger the aggregation of nonmagnetic particles, while the 1st RPS 
measures all four aggregates. By deducting the nonmagnetic aggregate counts from the 2nd 
RPS, an additional two biomarker concentrations can be measured in terms of the magnetic 
aggregate counts. If multiple two-stage RPS are integrated into a device, a large number of 
biomarkers can be detected via parallel detection. 
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5.4 Summary 
 
A multiplexed immunoaggregation assay was studied in this Chapter based on size 
and the magnetic properties of the MPs. Detection ranges from 5.20 to 208 ng/mL and 3.10 
to 51.2 × 103 ng/mL were achieved for human ferritin and rabbit anti-mouse IgG detection, 
respectively. The lower detection limits of the multiplexed immunoaggregation assay are 
3.10 ng/mL and 5.20 ng/mL for human ferritin and rabbit anti-mouse IgG, which are 
comparable to those of commercial ELISA kits (~6.0 ng/mL for human ferritin, and ~5.0 
ng/mL for rabbit anti-mouse IgG).  
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CHAPTER VI 
CELLULAR BIOMARKER DETECTION USING A TWO-STAGE MICRO 
RESISTIVE PULSE SENSOR 
 
 
 
6.1 Design concept and sensing principle 
 
 
Figure 6.1 Schematic of the two-stage resistive pulse sensor (two-stage RPS) for 
pathogen detection 
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Pathogen cells as a type of cellular biomarker are studied in this chapter. Pathogen 
detection represents an important task for many applications such as disease diagnosis, 
food industry, environmental monitoring, biodefense and biological research [7] [8] [9]. 
Rapid analysis is essential in pathogen detection, especially for diagnosis of pathogen 
infection and controlling the spread of disease [9]. In this chapter, I will present a two-stage 
resistive pulse sensor for pathogen cell detection based on a simple surface 
functionalization method by attaching antibody functionalized MPs (Ab-MPs) to the 
sensing surface via an applied magnetic field, requiring no chemical modification of the 
surface. Figure 6.1 shows the design concept of the two stage resistive pulse sensor (two-
stage RPS) for pathogen cell detection. Firstly, antibodies (Abs), which are specific to the 
receptors on surface of the target cells are immobilized on the MPs to form Ab-MP. Then, 
the Ab-MPs are captured in the capture chamber by an external magnet in order to 
functionalize the capture chamber with Ab-MPs. For each test, a sample solution 
containing target cells is loaded into the inlet reservoir of the two-stage RPS, then driven 
through the two-stage RPS. The total number of cells entering the capture chamber is 
counted by the 1st RPS. While target cells are captured in the capture chamber, non-target 
cells pass through the capture chamber and are counted by the 2nd RPS. The difference 
between the counts measured by 1st and 2nd RPS represents the count of target cells. 
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Figure 6.2 Images of the two-stage RPS including sensing channels, a capture chamber 
and three Ag/AgCl electrodes 
 
The device consists of: 1) two sensing channels with a width of 20 µm, height of 
20 µm and length of 30 µm to detect cell transits; 2) a capture chamber with a width of 1 
mm, height of 40 µm and a length of 15 mm; and 3) three Ag/AgCl electrodes to detect the 
resistive pulses. The two -stage PS was fabricated using standard soft lithography, as 
discussed section 3.11. 
 
6.2 Testing procedure and experiment setup 
 
To functionalize the capture chamber with antibody, at the beginning of each test, 
100 µL Ab-MPs were loaded in the inlet reservoir and driven through the capture chamber 
by the pressure difference between the inlet and outlet reservoirs, at a flow rate of 
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approximately 200 µL/hr. Two types of Ab-MPs were used in this study. They were the 
Saccharomyces cerevisiae antibody (Ab1, 1 mg/mL, Bio-Rad, USA) functionalized MPs 
(Ab1-MPs) and rabbit anti-mouse antibody (Ab2) functionalized MPs (Ab2-MPs). Ab-
MPs were prepared using the same procedure as discussed in section 3.3. Both Ab1-MPs 
and Ab2-MPs had a concentration of 7.2 × 104 count/µL. An external magnet (19 mm × 
19mm × 19mm, NdFeB, Grade N52, K&J Magnetics, Inc.) was used to capture the Ab-
MPs. After 50 µL of MPs were captured in the chamber, the remaining MPs were removed 
from inlet reservoir, and the inlet reservoir was washed by PBS buffer. Approximately 3.6 
× 106 Ab-MPs were loaded to the capture chamber, and were estimated to form ~2 layers 
of MPs (the estimated thickness of the Ab-MP coating is 5.3 µm).  
Two types of cells were tested in this study. Baker’s yeast (saccharomyces 
cerevisiae, Lalvin, Canada) was used as a target cell and algae (Chlorella, CAROLINA 
Biological, USA) was used as a non-target cell. Yeasts are a group of important model 
microorganisms for many biological studies [194]. Some species of yeast, for example 
Candida albicans, can cause infections in humans [195]. S. cerevisiae is well-known in the 
bakery and brewing industries. However, it is also reported as an unusual cause of life-
threatening infection in humans [150] [151]. In our study, S. cerevisiae is used as a model 
cell to prove the concept of the pathogen detection mechanism shown in Figure 6.1. 
Chlorella was used as the control cell, whose size is very close to that of S. cerevisiae to 
prove the device’s capability to differentiate target cells from similar sized reference cells. 
In our study, the concertation of S. cerevisiae was varied from 500 to 2000 cells/µL, while 
the Chlorella concentration was kept constant at 1000 cells/µL. The cell concentrations 
were measured using an Accusizer 780 particle sizer (Particle Sizing Systems, Port Richey, 
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FL, USA) before each test. We also measured the sizes of both cells using microscopes. 
The size ranges of S. Cerevisiae and Chlorella are from 3.2 to 7.4 µm and from 3.4 to 8.4 
µm, respectively. To prove that the use of Ab1-MPs is able to capture S. cerevisiae, 50 µL 
of S. cerevisiae was mixed with 50 µL of Ab1-MPs. The concentration of S. cerevisiae and 
Ab1-MPs were 1000 counts/µL and 7.2 × 104 count/µL, respectively. Then the sample was 
observed under a light microscope, as shown in Figure 6.3. 
 
 
Figure 6.3 S. cerevisiae captured by Ab1-MPs. The concentrations of S. cerevisiae and 
Ab1-MPs were 1000 count/µL and 7.20×104 count/µL, respectively 
 
Figure 6.3 shows that the Ab1-MPs are able to capture the S. cerevisiae. Next, the 
mixture of S. cerevisiae and Chlorella was tested by the two-stage RPS. At each test, 100 
µL of sample was loaded into the inlet reservoir at a flow rate approximately 20 µL/hr. To 
provide the pressure difference between inlet and outlet reservoir, the device was placed 
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vertically and cell samples were driven through the device by gravity. Thus, a bulky springe 
pump was not necessary. The flow rate was calculated using the volume difference before 
and after each test and the duration of each test. Resistive pulse responses were record at a 
sampling rate of 500 kHz. 
 
 
Figure 6.4 Typical resistive pulses generated by the two-stage RPS. The positive and 
negative pulses represent the passages of cells through the 1st RPS and 2nd RPS 
respectively 
 
Figure 6.4 shows typical resistive pulses generated by the two-stage RPS. A 7 µL 
mixture of S. cerevisiae and Chlorella was tested. Both S. cerevisiae and Chlorella had a 
concentration of 1000 count/µL. The equivalent circuit of two-stage RPS was discussed in 
5.1.2 (as shown in Figure 5.4). The positive and negative pulses represent the passage of 
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cells through the 1st and 2nd RPS, respectively. The cell size was back calculated using 
equation 3.1, and plotted in Figure 6.5. In this design, both width and height of the sensing 
channel are 20 µm. Thus the characteristic diameter, D, was calculated to be 22.57 µm by 
D = (4·A/π)1/2. The correction factor, F, was taken to be 1.0 [109]. 
 
 
Figure 6.5 Counts and size distribution measured from 1st RPS and 2nd RPS 
 
As shown in Figure 6.5, a total of 13.74 × 104 cells passed through the 1st RPS and 
entered the capture chamber, while 7.37 × 103 count Chlorella cells exited the chamber, 
implying 6.73 × 103 count S. cerevisiae were captured by the capture chamber. The total 
counts for S. cerevisiae and Chlorella are in good agreement with the actual numbers 
calculated from their concentrations (S. cerevisiae: 7 × 103counts, Chlorella: 7 × 103 counts 
and total counts: 14 × 103counts). 
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6.3 Capture efficiency of target and non-target cells 
 
The target cell detection of the two-stage RPS is based on an assumption that all 
target cells are captured by the Ab-MP layer while all non-target cells pass through the 
capture chamber. Accurate detection requires that the reduction of the cell counts between 
1st and 2nd stage RPS is caused by the specific capture of pathogen (S. cerevisiae) by the 
Ab-MP layer. However, in actual experiments, the reduction could also be caused by the 
nonspecific attachment of non-target cells (Chlorella). To prove the dominance of specific 
capture, experiments were conducted to evaluate the capture efficiency of specific and 
nonspecific attachment by the Ab-MP layer using two types of Ab-functionalized MPs: 1) 
anti-S. cerevisiae Ab-functionalized MPs (Ab1-MPs) coated on the capture chamber to 
evaluate the specific capture of S. cerevisiae, and nonspecific capture of Chlorella, and 2) 
rabbit anti-mouse Ab-MPs (Ab2-MPs) coated on the capture chamber to evaluate the 
nonspecific capture of S. cerevisiae and Chlorella, respectively. The cell concentration and 
flow rate were set to be 1000 count/µL and 20 µL/hr for both experiments. For each test, 
only one type of cell was used. The capture efficiency is defined as the ratio of the counts 
of cells exiting the capture chamber over the count of cells entering the capture chamber, 
both counts were obtained from the counts of two RPSs. Each test was repeated five times. 
The measurement results for capture efficiency of S. cerevisiae and Chlorella under two 
chamber surface conditions are shown in Figure 6.6. 
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Figure 6.6 Measured capture efficiency of S. cerevisiae and Chlorella. Both S. cerevisiae 
and Chlorella had a concentration of 1000 count/µL 
 
As shown in Figure 6.6, with Ab1-MPs, the capture efficiencies for S. cerevisiae 
and Chlorella were 95.5 ± 2.3% (specific capture efficiency) and 3.4 ± 1.5% (nonspecific 
capture efficiency). With the Ab2-MPs, the nonspecific capture efficiencies for S. 
cerevisiae and Chlorella were 3.1 ± 4.1%, and 1.4 ± 2.6%. Although the capture efficiency 
is highly dependent on the affinity of the antibody, the capture ligand and the contact time 
of the cell and the surface, the 95.5% capture efficiency is very high in this initial evaluation. 
Nonspecific attachment (<5%) is low, and is comparable with the nonspecific attachment 
reported by other studies [198] [8]. With the high specific capture efficiency and the low 
nonspecific capture efficiency, the proposed device is expected to differentiate and count 
pathogen cells accurately from a mixture with small errors. 
90 
 
To further reduce the nonspecific attachment, one possible solution is to use a large 
flow velocity and high shear stress in the capture chamber. A recent study showed that 
shear stresses ranging from 1.0 to 3.0 dyn/cm2 were optimal in CD4+ T cell capture [198]. 
The shear stress was estimated using following equation [199].[172],  
𝜏𝑤 = 6𝜇𝑄/(ℎ
2𝑤)                                                   (6.1) 
where τw is the shear stress at the walls of a rectangular channel, µ is the dynamic viscosity 
of the fluid, Q is the flow rate, w is the width of microfluidic channel and h is the height of 
the microfluidic channel. In our test, the dynamic viscosity of PBS buffer was 1 × 10-3 Pa·s 
[200], and the flow rate was 20 µL/hr. Hence the estimated shear stress is 0.21 dyn/cm2. 
By using a large flow rate, the large shear stress at the capture chamber wall may result in 
a low nonspecific attachment. However, a large flow rate may also wash away the Ab-MPs 
later; a strong magnetic field is required for a larger flow rate. In addition, nonspecific 
attachment can also be reduced by: 1) increasing the antibody density on the MP surface 
and the Ab-MP coverage on the sensing surface, and 2) using antifouling materials to 
modify the MP and sensor surfaces [201]. 
To prove that the two-stage RPS is able to accurately detect the target cell 
concentrations, pure S. cerevisiae with concentration ranging from 5 × 102 to 5 × 103 
count/µL were tested by both the two-stage RPS with Ab1-MPs coating on the capture 
chamber and the Accusizer. The capture chamber was coated with Ab1-MPs, which are 
expected to capture target cells with high efficiency. The cell counts measured by the 1st 
RPS indicates the target cell concentration while the cell counts measured by the 2nd RPS 
is used to calculate the capture efficiency at different target cell concentrations. 
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Figure 6.7 The S. cerevisiae concentrations measured by two-stage RPS. The gray area 
represents the measurement uncertainty of the Accusizer (±10%) 
 
The S. cerevisiae concentrations measured by two-stage RPS are shown in Figure 
6.7. The concentrations measured by the two-stage RPS (black circles) are in good 
agreement with those measured by the Accusizer. The measurement error ranges from 1.4 
to 4.7%, which proves that the two-stage RPS is able to measure the target cell concertation 
with small error. According to the count reduction measured by the 1st and 2nd RPS, the 
capture efficiency was calculated to range from 94.8% to 95.5%, which is high and 
comparable to the results report by other studies [198]. Two possible solutions to further 
increase the capture efficiency are: 1) using a longer capture chamber to improve 
interaction between the cells and Ab-MPs, and 2) using antibody or aptamer with higher 
binding affinity [202]. Another issue that may affect the measurement accuracy is that, at 
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a higher concentration, the increased chance of two cells transiting through two sensing 
channels at the same time may cause an increase of both R1 and R2 (see Figure 6.1), which 
will lead to incorrect counts and incorrect concentration measurements. This issue can be 
overcome by taking two independent measurements of the two RPSs, using two pairs of 
electrodes. 
 
6.4 Detection of target cells in a mixture with non-target cells 
 
 
Figure 6.8 S. cerevisiae detection in a mixed population of S. cerevisiae and Chlorella. 
The gray area represents the measurement uncertainty of Accusizer 
 
Figure 6.8 shows the S. cerevisiae detected in a mixed population of S. cerevisiae 
and Chlorella. In this experiment, the concentration of S. cerevisiae was varied from 5 × 
93 
 
102 to 2 × 103 cells/µL, while the concentration of Chlorella was kept constant at 1.019 × 
103 count/µL. The measured S. cerevisiae concentration vs the input concentration is 
plotted in Figure 6.8. For comparison, the y = x line (long dash line) and y = 1 × 103 
count/µL line (short dash line) are also plotted. The Chlorella concentration measured by 
our device and by the Accusizer at all S. cerevisiae concentrations was 1018 ± 92 count/µL 
and 1019 ± 69 count/µL, which agree with each other very well, indicating that the 
nonspecific capture efficiency is small. For S. cerevisiae measurement, the measured 
concentrations by the two-stage RPS device are accurate when the S. cerevisiae/Chlorella 
ratio (target cell to non-target cell ratio) is high (from 1.0 to 2.0). Compared to the 
Accusizer measurements, the measurement error ranged from 4% to 7%, which is well 
within the measurement uncertainty of the Accusizer. The best accuracy was achieved 
when S. cerevisiae and Chlorella have the same concentration. However, at lower S. 
cerevisiae/Chlorella ratio (0.1 to 0.5), the measurement error became higher, ranging from 
20% to 32%, which is 10% to 22% higher than the measurement uncertainty of the 
Accusizer. Note that the detection accuracy is affected by the ratio of target/non-target cells 
due to the nonspecific attachment of the non-target cells. At low target cell/non-target cell 
ratios, the detection accuracy decreases because even a small amount of nonspecific 
attachment causes a large error in the detection of target cells whose concentration is low, 
which is a universal challenge for all cell immunoassays. For example, a previous study 
demonstrated that 58.2% of target L. monocytogenes was captured when it was mixed with 
non-target S. Enteritidis at a 1:1 ratio[203]. In our experiment, the relative error on the S. 
cerevisiae concentration measurement was 4% when the S. cerevisiae/Chlorella ratio is 
1.0, indicating our method has a higher capture efficiency and higher accuracy. The 
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accuracy can be further improved by using a capture ligand with a higher affinity, a higher 
flow rate and/or antifouling surfaces [201].  
The advantages of the presented pathogen cell detection method are manifold. First, 
it eliminates the need for on-chip surface modification, which is typically difficult and time 
consuming for microchannels; second, the sensing surface can be functionalized just before 
each test using freshly-made Ab-MPs. This greatly improves the device reliability because 
antibody have a limited shelf life due to irreversible denaturation [79]. Third, the Ab-MP 
based capture surface enables a higher capture efficiency due to increased surface 
roughness. Fourth, the sensing surface functionalization can be regenerated quickly by 
removing the magnetic field and washing away the magnetic beads for next use. With these 
advantages, this device can potentially be used for a range of applications in addition to 
microorganism identification. For example, it can potentially be used for HIV diagnosis, 
where a CD4/CD8 T lymphocyte ratio less than one is a possible HIV indicator [204]. The 
device can also be extended to detect multiple types of pathogen cells in a single test by 
using multiple capture chambers in series, with each chamber coated with one specific Ab-
MP layer. 
 
6.5 Summery 
 
In this chapter, a two stage RPS was studied to detect target cell concentrations in 
a mixture with non-target cells. Antibody-functionalized MPs (Ab-MPs) were used to 
functionalize the capture chamber surface, and a two-stage resistive pulse sensor was used 
to detect the pathogen cells. A specific capture efficiency greater than 94.8%, and a 
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nonspecific capture efficiency as low as 3.4% were achieved. In the mixture measurements, 
for a S. cerevisiae/Chlorella ratio ranging from 1.0 to 2.0, the measurement error ranged 
from 4% to 7%, while the errors were 20% to 32%, for a ratio was 0.1 to 0.5. Without 
labelling or surface modification processes, this device enables fast and cost-effective 
pathogen detection and microorganism identification. 
 
  
96 
 
CHAPTER VI 
CONCLUSIONS AND FUTURE THOUGHTS 
 
 
 
7.1 Conclusions 
 
In this research, I developed label-free and multiplexed immunosensor chips based 
on resistive pulse sensing technology for detection of macromolecular and cellular 
biomarkers. First, a label-free biomarker detection device based on immunoaggregation 
and a micro resistive pulse sensor was invented. In the detection, specific biomarkers 
induced the aggregation of antibody functionalized MPs; the aggregates, whose volume 
fraction is indicative of biomarker concentration, were detected by the resistive pulse 
sensor. To demonstrate the device’s capability for biomarker detection, rabbit anti-goat 
IgG, as a model biomarker was measured and a detection range from 16 to 160 ng/mL was 
achieved. The volume fraction of aggregates was indicative of the biomarker concentration. 
The volume fraction of aggregates increases with an increase of biomarker concentration. 
Beyond the upper biomarker detection limit, the volume fraction of aggregates starts to 
drop, because the biomarkers saturate the binding sites on the MPs and prevent the 
formation of immunoaggregation. Human ferritin, as a biomarker to iron storage, was also 
tested  using  the  immunoaggregation  biomarker  sensor  in  10%  FBS to mimic the real 
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disease diagnosis environment. A detection range from 0.1 to 208 ng/mL was achieved. 
Experiments also found that the detection range can be tuned to lower concentration or 
higher concentration by using a lower or higher MP concentration. Compared with 
commercial ELISA kits, this label-free immunoaggregation assay based on the micro 
resistive pulse senor has a lower limit of detection (0.1 ng/mL for human ferritin) and 
requires less assay steps, making it a promising technique for onsite, highly sensitive 
biomarker analysis. Multiplexed immunoaggregation assays based on a two-stage resistive 
pulse sensor were also studied in this research for detection of multiple biomarkers at the 
same time. Detection ranges from 5.2 to 208 ng/mL and 3.1 to 51.2 × 103 ng/mL were 
achieved for human ferritin and mouse anti-rabbit IgG detection, respectively. The 
multiplexed immunoaggregation assay further promotes the capability of the micro 
resistive pulse sensor, and enables multiple biomarkers detection in a single test. 
For cellular biomarker detection, a two-stage resistive pulse sensor for pathogen 
measurement was also discovered in this research. Instead of chemical modification of the 
microchannel surfaces, antibody functionalized MPs were used to functionalize the capture 
chamber surface via an external magnetic field, and a two-stage resistive pulse sensor was 
used to detect the count of cells. S. cerevisiae was used as a model pathogen cell to test the 
sensor. A highly specific capture efficiency greater than 94.8%, and a nonspecific capture 
efficiency as low as 3.4% were achieved. The measurement of S. cerevisiae concentration 
in a mixture with Chlorella (control cell) was demonstrated. For a S. cerevisiae/Chlorella 
ratio ranging from 1.0 to 2.0, the measurement error ranged from 4% to 7%. While the 
error was 20% to 32%, for the ratio range from 0.1 to 0.5, which is lower than that of prior 
research on cell detection with a low target cell/non-target cell ratio. Without labelling or 
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surface modification processes, this device enables fast and cost-effective pathogen 
detection and microorganism identification. 
The invented devices for macromolecular and cellar biomarker detections are label 
free, require no surface modifications for the microchannels, and hence are advantageous 
for developing low cost alternatives in biomarker detection analysis. It is a powerful 
complement to ELISA for biomarker assay. They can potentially be used for disease 
diagnosis/prognosis, biodefense, environmental monitoring, food and water safety and 
biological research. 
 
7.2 Future thoughts 
 
For macromolecular biomarker detection, the immunoaggregation assays based on 
the micro resistive pulse sensor technologies were applied for the detection of three types 
of macromolecule biomarkers. The micro resistive pulse sensor based immunoaggregation 
assay can also be applied to detect various bio-objects including bacterial, fungal and other 
macromolecule including hormones and proteins, DNA etc., as long as high binding 
affinity antibody/aptamer probes can be found. To detect additional biomarkers (>3), it is 
convenient to increase the multiplexed capacity using a multichannel device with a large 
number of detectors. In order to multiplex/encode the multichannels, one possible solution 
is frequency division multiplexing [191]. However, a limited number of sensing channels 
can be added to the multichannel devices because of the narrow frequency range in which 
the resistive pulse sensors have a resistive behavior [163]. Most MP multiplexing/encoding 
strategies are designed for optical detection, they require accurate alignment of optics, 
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extremely high resolution detection and a decoding algorithm which makes these methods 
bulky, expensive and time-consuming. It is convenient to use micro resistive pulse sensing 
technology for MP based multiplexing/encoding. One possible multiplexing strategy is to 
use MP tags (MP tags) with variable cross-section, as show in Figure 7.1. 
 
 
Figure 7.1 Design concept and sensing principle for the MP tags based multiplexed 
detection 
 
Figure 7.1 shows the design concept and sensing principle for a multiplexed 
immunoaggregation assay based on MP tags. The MP tag has a variable cross-section (four 
segments, as shown in Figure 7.1). One end of the MP tag is immobilized with antibody. 
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After the MP tags are mixed with the sample, the specific binding between target 
biomarkers and antibody immobilized on the MP tags triggers the aggregation of MP tags. 
The formed MP tag aggregates are “end-to-end” type aggregates. The “end-to-end” 
aggregates has been proven by other studies [99]. When an MP tag aggregate passes 
through the sensing channel it will generate a resistive pulse and the amplitude of this 
resistive pulse is proportional to the cross-section of the MP tag [162]. For example, the 
aggregate formed by two MP-Tag1 has eight segments (each MP Tag1 has 4 segments), 
thus the resistive pulse generated by this aggregate will drop eight times during the transit 
of the aggregate, which can be marked as a digital signal “1111”. In comparison, the 
resistive pulses generated by MP-Tag2 aggregates can be identified as “1011”. The unique 
resistive pulse signature is used to identify the MP tags. With N segments, the maximum 
multiplexed capacity is 2N. Both rod sharp [99] or thin film [30][145] particles can be used 
as MP tags. Two fabrication methods of MP tags are electrodeposition [126] [32] and 
lithography [30] [145]. The use of this type of MP tag can significantly increase the 
multiplexed capability of a micro resistive immunoaggregation sensor. However, several 
issues must be addressed before using MP tags. Firstly, in order to eliminate the rotation 
of MP tags, hydro-focusing is required to focus the MP tags in the center of the 
microchannel. Secondly the length of the sensing channel should be short enough (~10 µm) 
to differentiate each segment of the MP tags. 
In terms of multiplexed cell detection, one possible strategy is to use a capture 
chamber array, as shown in Figure 7.2 (a). This device consists of a 2 × 3 capture chamber 
array coated with different Ab functionalized MPs, which is able to detect six types of 
target cells in a single test. Each capture chamber is monitored by a pair of RPSs. A total 
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of 8 RPSs will be integrated in this device. Each RPS is modeled as a variable resistance 
as shown in Figure 7.2 (b) and measured independently.  
 
 
Figure 7.2 (a) Design concept of a 2 × 3 capture chamber array for multiplexed pathogen 
cell detection. (b) Equivalent circuit of the RPS array 
 
Figure 7.2 shows the design concept of a 2 × 3 capture chamber array for 
multiplexed pathogen cell detection. For each test, cell samples are loaded into the two 
inlet reservoirs and driven through each capture chamber. Each chamber is coated with one 
type of Ab-MPs and able to capture one type of target cells. A pair of RPSs are used to 
monitor the counts of target cells captured by each chamber. The concentration of target 
cells is then calculated by using the counts of target cells captured in each chamber divided 
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by the volume of sample passing through each chamber (assuming the volume of each 
chamber is negligible comparing with the volume of cell sample). 
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